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ABSTRACT: 
 
The metabolic syndrome (MetS), a cluster of risk factors for cardiovascular disease and type 
2 diabetes, is associated with low-grade inflammation, a state in which several cytokines 
are secreted from adipose tissue. Decreased adiponectin and increased interleukin-1 
receptor antagonist (IL-1Ra) levels have been observed with the MetS. Elevated levels of C-
reactive protein (CRP), a general inflammatory marker, often appear with metabolic 
diseases. There is existing evidence of gender differences in relation to the MetS as a 
cardiovascular risk or inflammatory markers associated with metabolic diseases. The role of 
low-grade inflammation in the development of these diseases is not well-known. 
This study was aimed at obtaining gender-specific information about the association of 
adiponectin and low-grade inflammation, measured by high sensitivity- CRP (hs-CRP) and 
IL-1Ra,  with the factors that often precede the MetS (e.g. weight gain, elevated blood 
pressure and smoking), and with the course of the MetS. The study population consisted of 
five age groups of inhabitants in the town of Pieksämäki (n=1294), who were invited for a 
health check-up in 1997-1998 and again in 2003-2004. Of the invited subjects, 923 (71.3%, 411 
men and 512 women) participated in the first check-up and 681 subjects of them in the 
second check-up. 
The results indicate that decreased adiponectin and increased hs-CRPand IL-1Ra levels 
were associated with a relative change in body mass index from the age of 20 years to 
middle age in women, but not in men. The proportion of women with lower socio-
economical status increased with relative weight gain; in men there was no association.  
Decreased adiponectin levels in females and increased hs-CRP levels in males were 
associated with smoking. Women with elevated blood pressure and the MetS had 
significantly higher levels of hs-CRP and IL-1Ra compared to men. The risk for the MetS 
was threefold in hypertensive women with the lowest tertile of adiponectin; no association 
was seen in men. Decreased baseline adiponectin and increased baseline IL-1Ra levels were 
associated with both the appearance and the persistence of the MetS; increased baseline hs-
CRP levels were linked with the persistence of the MetS. 
In conclusion, from the aspect of low-grade inflammation, greater relative weight gain is 
more harmful to women than to men. Women, who smoke may be more prone to 
development of inflammatory state due to decreased adiponectin levels compared to men. 
Decreased adiponectin level and increased low-grade inflammation may refer to an 
unfavorable course of the MetS in both genders. 
National Library of Medicine Classification: WG 340, WK 820, WD 200  
Medical Subject Headings: Metabolic Syndrome X; Adiponectin; Smoking; C-Reactive Protein; Hypertension; 
Interleukin 1 Receptor Antagonist Protein; Sex Factors; Body mass index  
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TIIVISTELMÄ: 
 
Metabolinen oireyhtymä, sydän- ja verisuonisairauksien ja diabeteksen riskitekijöiden 
keräytymä, on yhteydessä matala-asteiseen tulehdukseen. Metabolisissa sairauksissa on 
havaittu alentuneita adiponektiinin ja kohonneita interleukiini-1 reseptori antagonistin (IL-
1Ra) ja C-reaktiivisen proteiinin (CRP) pitoisuuksia. Tulehduksen merkkiaineiden 
pitoisuuksissa sekä metaboliseen oireyhtymään liittyvässä sydän- ja verisuonisairauksien 
riskissä on havaittu sukupuolten välisiä eroja. Matala-asteisen tulehduksen merkitys 
metabolisten sairauksien kehittymisessä tunnetaan vaillinaisesti. 
Tämän tutkimuksen tarkoituksena oli lisätä tietoa matala-asteisen tulehduksen 
yhteydestä metabolista oireyhtymää usein edeltäviin tekijöihin – painon nousuun, 
kohonneeseen verenpaineeseen ja tupakointiin – sekä tutkia mahdollisia sukupuolten 
välisiä eroja. Tutkimusväestö muodostui Pieksämäen kaupungin viidestä ikäluokasta, jotka 
kutsuttiin terveystarkastukseen vuosina 1997–1998 ja uudelleen 2003–2004.  
Tutkimuksessa havaittiin, että naisilla suhteellisen painoindeksin (BMI) nousu 20 
vuoden iästä keski-ikään oli yhteydessä merkitsevästi alentuneeseen 
adiponektiinipitoisuuteen ja lisääntyneeseen herkän CRP:n (hs-CRP) ja IL-1Ra:n 
pitoisuuteen. Alempaan sosiaaliluokkaan kuuluvien naisten osuus lisääntyi merkitsevästi 
painon nousun myötä. Miehillä tulehduksen merkkiaineilla tai sosiaaliluokalla ja BMI:n 
muutoksella ei ollut yhteyttä. Naisilla havaittiin yhteys tupakoinnin ja matalan 
adiponektiinipitoisuuden välillä. Miehillä oli todettavissa yhteys kohonneen hs-CRP:n ja 
tupakoinnin välillä. Naisilla, joilla oli kohonnut verenpaine ja metabolinen oireyhtymä, oli 
merkitsevästi suuremmat hs-CRP – ja IL-1Ra-pitoisuudet kuin vastaavilla miehillä. Naisilla 
adiponektiinipitoisuuden alimpaan kolmannekseen liittyi kolminkertainen riski saada 
metabolinen oireyhtymä. Miehillä tätä yhteyttä ei ollut. Tässä tutkimuksessa lähtötason 
alentunut adiponektiinipitoisuus ja suurentunut IL-1Ra -pitoisuus liittyivät metabolisen 
oireyhtymän ilmaantumiseen ja pysyvyyteen. 
Johtopäätöksenä voidaan todeta, että matala-asteisen tulehduksen näkökulmasta 
suurempi suhteellinen painonnousu on haitallisempaa naisille kuin miehille. Tupakoivilla 
naisilla havaittu matalampi adiponektiinitaso tupakoiviin miehiin verrattuna voi viitata 
tupakoivien naisten olevan alttiimpia matala-asteisen tulehduksen kehittymiselle. Matala 
adiponektiinipitoisuus ja suurentunut tulehdusmerkkiaineiden taso ennakoi tämän 
tutkimuksen mukaan epäsuotuisaa metabolisen oireyhtymän kulkua molemmilla 
sukupuolilla. 
Yleinen suomalainen asiasanasto: metabolinen oireyhtymä; adiponektiini; c-reaktiivinen proteiini; 
interleukiinit; painoindeksi; sukupuolierot; tupakointi; verenpainetauti 
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 1 Introduction 
The metabolic syndrome (MetS) is a cluster of classical risk factors like hypertension, 
dyslipidemia, glucose intolerance and obesity, which are associated with cardiovascular 
diseases (CVD) and type 2 diabetes (T2D) (1, 2, 3). There is still no conclusive idea of the 
pathophysiology of the MetS (3). There are also multiple definitions of the MetS. This has 
caused confusion and the question of the clinical usefulness of this syndrome has been    
raised; does the MetS identify subjects at risk for CVD or T2D better than traditional risk 
scores? Though no consensus exists, there is significant evidence showing that traditional 
risk factors tend to be aggregated in an individual and, moreover,  subjects with the MetS 
have increased risk for CVD and T2D (4, 5, 6). 
Obesity and the MetS are nowadays known to be associated with low-grade 
inflammation (7). In this condition, a variety of cytokines are secreted mainly from adipose 
tissue, which is thus considered as an important endocrine organ (8). Decreased levels of 
anti-inflammatory adiponectin have been detected in connection with coronary artery 
disease, central obesity and the MetS (8-13). There is also evidence suggesting that 
adiponectin has a role in regulation of the inflammatory network (14). Elevated levels of 
interleukin-1β (IL-1β), one of the major pro-inflammatory cytokines, and interleukin-1 
receptor antagonist (IL-1Ra) have been detected in obesity and features of the MetS (15-20). 
In addition, the well-known marker of inflammatory conditions, C-reactive protein (CRP), 
is elevated in CVD, obesity and the MetS; furthermore, levels of CRP seem to be regulated 
by inflammatory cytokines and centrally located adiposity (21-25). Smoking, the traditional 
risk factor for CVD, is also associated with central fat accumulation and increased levels of 
inflammatory markers (26, 27).   
Aside from obesity itself, fat distribution seems to play a role in the development of 
metabolic disorders. In particular, visceral fat deposits contribute to insulin resistance and 
are associated with CVD risk and the MetS (28, 29, 30). There have been observed gender 
differences in the risk of CVD and T2D in relation to fat distribution, the levels of 
inflammatory markers and the MetS (31-34). Additionally, diabetic women seem to be at 
higher risk of CVD events, compared to diabetic men (35, 36). Also, IL-1β and IL-   1Ra 
secretions are regulated differently between genders (37). 
With the increase in obesity and the number of diabetic subjects there exists a great 
challenge to identify early enough those individuals with an increased risk for CVD and 
T2D. The MetS may help in estimating this risk. However, a better understanding of the 
pathophysiology of the MetS would increase the usefulness of this risk cluster in clinical 
practice.  
Due to the growing evidence of the involvement of low-grade inflammation in the 
pathophysiology of the metabolic disorders, this population-based study was aimed at 
obtaining new, gender-specific information about the association of adiponectin and low-
grade inflammation with factors that often precede the MetS – like weight gain, elevated 
blood pressure and smoking – and getting   information about the markers of low-grade 
inflammation related to the course of the MetS.  
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2 Review of the literature 
2.1 METABOLIC SYNDROME 
2.1.1 Brief history with different definitions of the metabolic syndrome 
Hypertension, hyperglycemia and gout are often found in the same people. This was first 
noticed by the Swedish physician Kylin in 1923. His finding is commonly considered as the 
first description of the metabolic syndrome (MetS) (38). More than 20 years later, Vague 
published research results showing upper-body (android or male-type) adiposity 
associated with the metabolic disturbances repeatedly seen with cardiovascular disease 
(CVD) and type 2 diabetes (T2D) (39). Subsequently, associations between obesity and 
lipids and glucose metabolism, and their possible connections with CVD have been under 
investigation (40, 41). These disturbances were not, however, considered as a cluster of risk 
factors until Reaven in 1988 described “Syndrome X”, a combination of hypertension, 
abnormal glucose metabolism, hypertriglyceridemia, low levels of high-density lipoprotein 
(HDL) cholesterol and hyperinsulinemia, which increases the risk of CVD and T2D (42). 
According to Reaven, insulin resistance with compensatory hyperinsulinemia was the 
central part of this syndrome, but he did not include obesity itself to be an etiological factor. 
Afterwards this cluster came to be called by other names, such as “The Insulin Resistance 
Syndrome” (43) or “The Deadly Quartet” (44). In the first attempt of a worldwide definition 
for this constellation of risk factors, the term “metabolic syndrome” was recommended, 
and although there has been competition between this term and others, “metabolic 
syndrome” is nowadays preferred and has gradually become established.  
In 1998, the World Health Organization (WHO) published the first worldwide definition 
for the MetS (45). This definition was based on insulin resistance (defined by 
hyperinsulinemia, impaired glucose tolerance (IGT) or T2D as a basic component). At least 
two of the additional factors (obesity, hypertriglyceridemia, low HDL cholesterol levels, 
hypertension and microalbuminuria) were needed to fulfill the MetS criteria in this 
definition (Table 1). The primary purpose of the WHO definition was to identify those 
individuals with the MetS who were at high risk of developing CVD or, among non-
diabetics, developing T2D. In practice, this definition proved difficult to use. The oral 
glucose tolerance test (OGTT) could be required, and among subjects with normal glucose 
tolerance, insulin resistance was proven with the expensive and time-consuming glycemic 
clamp technique. Additionally, the WHO definition was criticized because of the inclusion 
of microalbuminuria in the criteria, while there was no consensus about the association of 
microalbuminuria with insulin resistance (46, 47). 
The European Group for the Study of Insulin Resistance (EGIR) published the following 
year a modified criteria for the MetS with the purpose of establishing a more suitable tool 
for practice (48). Insulin resistance was also the essential component in this definition, but it 
was defined by fasting insulin. Two or more of the additional factors (obesity, 
dyslipidemia, hypertension and elevated fasting glucose) were required for the diagnosis of 
the MetS. Meanwhile, microalbuminuria was removed from the criteria. Central obesity 
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was determined for the first time in this definition with sex-specific limits of waist 
circumference instead of waist-to-hip ratio (WHR), which was used in the earlier definition. 
Furthermore, different cut-off points were used in dyslipidemia compared to the WHO 
definition. In the EGIR definition, diabetic subjects were excluded. (Table 1) 
A new approach to determining the MetS was undertaken in 2001 by the National 
Cholesterol Education Program (NCEP) Panel on Detection, Evaluation and Treatment of 
High Blood Cholesterol in Adults (Adult Treatment Panel III, ATP III) with a definition that 
equally treated each component (waist circumference, hypertriglyceridemia, low HDL 
cholesterol levels, blood pressure and glucose) (1). The MetS was defined by the existence 
of three or more of the abovementioned factors, which made this definition simple to use in 
clinical practice. Another notable difference, compared to the two earlier definitions, was 
the lack of insulin resistance determination in this definition. (Table 1) 
Two years later, the American Association of Clinical Endocrinologists (AACE) returned 
to the first two definitions of the MetS by introducing a new definition which included 
insulin resistance as its central focus (49). It also recommended the use of the term “Insulin 
resistance syndrome”. This definition had IGT, dyslipidemia with reduced HDL cholesterol 
or elevated triglycerides, elevated blood pressure and obesity as its major criteria; other 
factors which could affect the MetS diagnosis were a family history of CVD or other 
atherosclerotic diseases, or T2D, polycystic ovary syndrome and hyperuricemia. Diabetic 
subjects were excluded from this definition. (Table 1) 
Multiple different definitions of the MetS caused confusion both in practice and in 
research work. Additionally, it proved necessary to take ethnicity into account (e.g. the 
increased risk for T2D or CVD appeared in Asians with lower body mass index (BMI) and 
waist circumference, compared to Europeans) (50 - 53). In 2005, the International Diabetes 
Federation (IDF) published new criteria for the MetS in which central obesity was a 
compulsory basic element (54). Central obesity was evaluated by waist circumference with 
ethnic- and gender-specific cut-off points. Otherwise, at least two additional factors (such 
as fasting glucose, HDL cholesterol, fasting triglycerides and hypertension) were needed 
for the MetS diagnosis. The cut-off points in these parameters were similar to the ATP III 
definition, except for lower fasting glucose, which was adopted according to the new 
criteria of impaired fasting glucose recommended by the American Diabetes Association 
(ADA) in 2003, in which hyperglycemia is determined by fasting glucose ≥ 5.6 mmol/l (55).  
The same cut-off point of glucose was included in the later updated NCEP/ATP III 
criteria, which otherwise stayed unchanged, compared to the original criteria. There was 
seen to be no reason to make other changes in this updated ATP III criteria; by this 
argument, the definition placed no emphasis on a single underlying factor of the MetS (4). 
The task of unifying the diagnostic criteria of the MetS is ongoing. The representatives of 
IDF and the National Heart, Lung and Blood Institute (NHLBI) / American Heart 
Association (AHA) have tried to solve the remaining disagreements, giving a statement in 
2009 on the new clinical diagnostic criteria of this syndrome (56). They agreed that waist 
circumference should not be a prerequisite for diagnosis, but instead one of five criteria; the 
diagnosis is made on the basis of three criteria being present.(Table 1) Furthermore, it was 
acknowledged that waist circumference needs long-term prospective studies to be 
determined with adequate ethnic- and gender-specific limits. 
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2.1.2 Prevalence of the metabolic syndrome 
Estimation of the prevalence of the MetS is dependent on the definition used, as well as on 
the age, gender and ethnic make-up of the population. Among 8608 U.S. adults included 
in the Third National Health and Nutrition Examination Survey (NHANES) cohort in 
1988-1994, the age-adjusted prevalence of the MetS was 23.9% (using the NECP definition) 
and 25.1% (according to the WHO definition) (57). When the revised NCEP definition was 
used for 6436 subjects from the NHANES III, the age-adjusted prevalence was 29.2%; for 
the 1677 subjects in the NHANES 1999-2000 cohort, the age-adjusted prevalence was 
32.3% (58). For the 3601 subjects in the NHANES 1999-2002 cohort, the unadjusted 
prevalence was 34.5% on the basis of the NCEP definition and 39.0%, according to the IDF 
definition (59). When the WHO, NCEP and IDF criteria were compared in relation to 
middle-aged adults from the San Antonio Heart Study, the NCEP criteria showed 
increased prevalence compared to the WHO, but lower prevalence compared to the IDF 
criteria (60). 
Outside the USA, the prevalence of the MetS has also been reported to vary with the 
definition used. In an Australian population-based survey of more than 11,000 subjects 
(AusDiab), the prevalence of the MetS according to NCEP, WHO, IDF and EGIR 
definitions was 22.1%, 21.7%, 30.7% and 13.4%, respectively (61). Among a population of 
African origin, prevalence of the MetS was also estimated to be higher with the IDF 
definition, compared to the NCEP and the WHO definitions (30.3%, 28.1%, 24.8%, 
respectively) (62). In an Indian epidemiological study (CURES-34), the MetS prevalence 
estimates were 25.8% using the IDF, 18.3% using the NCEP and 23.2% using the WHO 
definitions (63). Though prevalence of the MetS often seems to be higher with the IDF 
definition, the opposite also appears, with lower prevalence when using the IDF criteria 
compared to the NCEP definition (64, 65).  
Inconsistent definition-related differences in the prevalence of the MetS may be due to 
ethnic-specific waist circumference included in the IDF definition. Additionally these 
prevalence rates depend on whether diabetic subjects are or are not included in the study 
population.  
In terms of the prevalence estimates of the MetS, there is some variation between 
genders. In the NHANES III, the age-adjusted prevalence rates in men were slightly 
higher compared to women (31.4% vs. 27.0%, respectively) whereas in the NHANES 1999-
2000 cohort the prevalence of the MetS showed a trend of being greater in women than in 
men (32.9% vs. 31.8%) (58). Although, prevalence estimates in many studies usually only 
vary by some percentages between genders, there are other studies with a wide range 
between gender-specific prevalence rates of the MetS: in males in a representative 
Australian population, prevalence rates were noticeably higher compared to women 
(24.4% vs. 19.9.% with ATP: III and 34.4% vs. 27.2% with IDF criteria); in a Greek 
population of 2282 subjects, the prevalence rates were 25.2% in men and 14.6% in women 
(ATP:III criteria); and in the FINRISK cohort of 2049 middle-aged subjects, the prevalence 
of the MetS was 38.8% in men and 22.2% in women, according to the WHO definition (61, 
66, 67). On the other hand, there is also evidence of greater prevalence rates among 
women compared to men:  
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in a Chinese population of 15540 subjects (17.8% vs. 9.8% with ATP: III), in the study of 
10368 subjects in Iran (40. 5% vs. 24% with ATP: III, 41.0% vs. 21.0% with IDF), and in a 
Spanish study (28.8% vs. 22%, n=2540, with ATP: III) (68, 69, 70). Accordingly, the 
prevalence estimates of the MetS between genders vary inconsistently. According to the 
literature to date, the reason for this gender-specific difference between the MetS 
prevalence rates is actively under investigation. It has been speculated that it is related to 
various factors like hormonal, socio-economical, occupational and more widely cultural 
aspects (71-77). Naturally gender-specific variations in MetS prevalence may be partly 
explained by the racial or ethnic composition of studied populations (57). 
The prevalence of the MetS is clearly age-dependent. In the NHANES III cohort, the 
prevalence rates between three age groups (20-39 years, 40-59 years and ≥ 60 years) of 
males were 10.2%, 29.3% and 42.6%, respectively. In females, the corresponding rates were 
9.7%, 26.0% and 43.9%, respectively (58). Age-related increases in MetS prevalence have 
been observed worldwide (63, 65, 66). However, a decrease or a plateau after the sixth or 
the seventh decade of life occurs in the prevalence of the MetS in some studies (66, 78). 
This may be explained by higher mortality, caused especially by metabolic disorders or 
obesity-related diseases in these age groups.  
With increasing obesity in younger age groups, features of the MetS are also found in 
children and adolescents (79). Diagnosis of the MetS in these age groups is difficult 
because of the lack of consensus of what criteria or definition to use (80, 81). This also 
entails difficulties when estimating prevalence of the MetS in children or adolescents (82). 
On the other hand, there is strong evidence that metabolic disorders present in childhood 
are important predictive factors for cardiovascular risks in adulthood (83, 84). 
In Finland, one of the first studies to determine the prevalence on the MetS was 
conducted in 1993-94, before any international definition of this syndrome was assessed. 
The MetS was defined as a clustering of dyslipidemia (hypertriglyceridemia, low HDL 
cholesterol, or both) and insulin resistance (abnormal glucose tolerance, hyperinsulinemia, 
or both), with the result that the MetS was present in 17% of men and in 8% of women 
(85). The MetS was also found to be more common in men in another Finnish study, where 
NCEP and IDF definitions of the MetS were compared in a non-diabetic population in the 
years 1992 and 2002. According to NCEP criteria, the MetS was present in 45.4% of men in 
1992 and in 46.9% of men in 2002. In women, the corresponding rates were 28.4% and 
35.5%, respectively. When the IDF criteria were used, 48.7% of men vs. 34.5% of women 
had MetS in 1992 and 49.7% of men vs. 42.2% of women in 2002. The notable thing in these 
rates is the fact that although the prevalence of the MetS increased in both genders over 
this period of ten years, the increase was statistically significant only in women: p=0.002 
(according to NCEP) and p=0.001 (according to IDF criteria) (86). The researchers found 
the increase in prevalence could be explained by increasing abdominal obesity and 
abnormalities in glucose metabolism. With increasing obesity, it can be assumed that MetS 
prevalence rates will increase worldwide in the future. 
2.1.3 Characteristics of the metabolic syndrome  
Classical components of the MetS are insulin resistance, presented as a central part of this 
syndrome by Reaven (42) and hypertension, glucose intolerance, dyslipidemia and also 
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(abdominal) obesity (44). Several other conditions (like the prothrombotic state, the pro-
inflammatory state, endothelial dysfunction, hyperuricemia, polycystic ovary syndrome 
and obstructive sleep apnea) are associated with the MetS (4, 87). The prothrombotic state 
and the pro-inflammatory state were even considered as major components of this 
syndrome in the report of the NHLBI/AHA conference in 2004 (88). Genetics, hormonal 
factors, lifestyle aspects (like physical activity, smoking and diet), socio-economical factors 
and aging also have an effect on the development of features of the MetS.  
An alternative way of classifying the components of the MetS is to divide them by 
metabolic risk factors and underlying risk factors. The metabolic risk factors are well-
known risks for atherosclerotic cardiovascular diseases like dyslipidemia, elevated plasma 
glucose and hypertension, while insulin resistance, abdominal obesity, and associated 
conditions (e.g. physical inactivity, aging and hormonal alterations, the pro-inflammatory 
state) are considered as underlying risk factors (4). 
Thus, the concept of the MetS is multidimensional. As seen in different definitions of 
the MetS, there are varying opinions of which components of the MetS are the most central 
ones and which factors play secondary roles. The fact that the MetS appears individually 
with different components present in one person (4) shows further challenges, both to 
research and clinical work concerning the MetS.  
 
 
 
 
 
 
 
 
      
      
 
 
 
 
 
Figure 1. Conditions involved with the development of the metabolic syndrome (METS) 
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2.2 PATHOPHYSIOLOGY OF THE METABOLIC SYNDROME 
Competing theories have made multiple attempts to explain the pathophysiology of the 
MetS. On the other hand, it is generally acknowledged that for a syndrome with this many 
features there is no possibility of finding a single or common cause, but instead there are 
several factors which affect the development of the MetS (4). In the AHA/NHLBI 
conference report, these factors have been grouped into three categories: obesity and 
associated adipose tissue-derived factors, insulin resistance, and independent factors that 
mediate components of the MetS. In every category, there are both genetic and acquired 
underlying causes. Additionally in this report, contributing factors such as aging, pro-
inflammation and multiple endocrine factors are mentioned (88). On the other side, there 
are researchers who consider insulin resistance to be the only factor capable of uniting the 
components of the MetS, and thus consider it to be the main pathogenic cause (87, 89). 
With obesity increasing worldwide and, furthermore, the present knowledge of how 
adipose tissue acts as an active endocrine organ and can secrete a variety of anti- and pro-
inflammatory cytokines, the present conception of the pathophysiology of the MetS 
includes visceral obesity and low-grade inflammation in particular as remarkable factors  
(7, 14, 90, 91, 92). Hypoadiponectinemia has also been considered as a link between insulin 
resistance and obesity (93). (Figure 1) 
2.2.1 Insulin resistance 
Insulin, the hormone secreted by β-cells in the islets of Langerhans, has multiple effects on 
carbohydrate, lipid and protein metabolism. Insulin acts as the main regulator of blood 
glucose levels: insulin concentration is elevated with the rise of blood glucose levels and 
stimulates glucose uptake in muscle cells and adipocytes. It also inhibits hepatic glucose 
production by inhibiting gluconeogenesis in the liver. Insulin regulates lipid metabolism 
by both stimulating lipogenesis and inhibiting lipolysis. A condition of impaired insulin 
action in its main target tissues, liver, skeletal muscle and adipocytes is referred to as 
insulin resistance, though insulin resistance is often determined in a more glucocentric 
way, with impaired insulin action resulting in hyperinsulinemia to maintain euglycemia 
(87, 90, 91). 
Insulin resistance has been identified and measured with multiple markers. The 
euglycemic hyperinsulinemic clamp is considered as a golden standard, although it is time 
consuming and expensive. For that reason e.g. fasting insulin and OGTT as well as 
computational models, the homeostatic model assessment (HOMA) and the quantitative 
insulin check index (QUICKI) have been used both in clinical and in research work to 
determine insulin resistance (6, 94). Both of the models mentioned have proven to be 
useful tools both in research and clinical work and even comparable to the euglycemic 
hyperinsulinemic clamp, especially in obese subjects (94). 
During the fasting state, the skeletal muscle energy supply comes mainly from fat 
oxidation and it is changed into glucose oxidation with the rise of blood glucose levels 
(95). Elevated blood glucose levels stimulate insulin secretion, which in turn suppresses 
lipolysis and increases glucose uptake into muscle cells. Glucose uptake is the main 
function of insulin as muscle tissue is concerned; and skeletal muscle because of its large 
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quantity plays a valuable role in maintaining glucose homeostasis (91, 96). As much as 
90% of the glucose uptake occurs in skeletal muscle (97). 
The fact that insulin resistance is associated with obesity has been well-known for 
decades. It has since been demonstrated that insulin resistance appears with weight gain 
even when weight still remains within normal limits, and also when obese subjects still 
have normal glucose tolerance (98, 99). Muscle insulin resistance is associated with an 
accumulation of fat in muscle tissue, especially in intramyocellar spaces (100). There is an 
overabundance of free fatty acids (FFA) in blood circulation because triglycerides stored in 
adipose tissue are free to mobilize in the absence of the antilipolytic effects of insulin (101). 
Triglycerides have been hypothesized to independently interfere with insulin action in 
muscle, but on the other hand there is also evidence that they would act as a surrogate 
marker for some other fatty-derived factor, most likely long-chain acyl-CoA species, which 
have been found to exist in muscle cells in a strong negative correlation with insulin 
sensitivity (102, 103). Long-chain acyl-CoA is involved in the destruction of the insulin-
signaling cascade, which normally begins with the insulin binding to its receptor (102). 
Increased intramyocellar fat and fatty acid metabolites are possibly the main factors in the 
development of insulin resistance in skeletal muscle. This theory is supported by the 
finding that in subjects with high BMI but low intramyocellar lipids, there is observed 
normal insulin sensitivity; controversially, in a lean subject with low BMI but high 
intramyocellar lipids, decreased insulin sensitivity appears (102). The cause for this 
unfavorable development is still inadequately known and may also involve genetic, 
inherited and inflammatory defects, in addition to obviously acquired cause, like obesity 
(104, 105). 
An excess of FFAs also contributes to the development of insulin resistance in the liver 
by enhancing hepatic glucose output and the production of triglycerides, as well as an 
increased secretion of very low-density lipoproteins (87, 90). Additional impairments in 
lipid metabolism include a decrease in HDL cholesterol and an increased density of LDL 
(87). Increased hepatic glucose production leads to an increased secretion of insulin, which 
however is not capable of suppressing glucose secretion; thus there is insulin resistance in 
the liver. Paradoxically, in this insulin resistance state, regarding lipid metabolism, the 
insulin action in the liver is strengthened with insulin contributing to the liver’s ability to 
produce more triglycerides (102).  
Insulin resistance of adipose tissue is firmly associated with the MetS (88, 89, 90, 102). 
Overabundance of FFAs reduces glucose uptake in adipocytes and, in the state of insulin 
resistance, lipolysis is accelerated with diminished insulin action, leading to a further 
increased release of FFAs (106). Centrally and viscerally located adipose tissue contributes 
especially to increased FFA flux and insulin resistance (107, 108, 109). Visceral adipocytes 
have been observed to be more sensitive to lipolysis than adipocytes in subcutis (110). 
According to portal theory, this excessive visceral lipolysis causes the liver to turn insulin 
resistant with direct drainage of FFAs to portal circulation. This theory has recently been 
convinced in an animal model (111). Additionally, adipose tissue seems to induce insulin 
resistance with the pro-inflammatory cytokines it secretes (112).  
Insulin receptors are commonly expressed in several tissues. Insulin action is described 
as an insulin signaling pathway which begins with insulin binding to its receptor. This 
10 
 
 
binding exerts a chain of phosphorylation-dephosphorylation reactions, which affect 
glucose transportation, glycogen synthesis and glycolysis, for example (104). In muscle 
cells, insulin binding to its receptors leads to tyrosine phosphorylation of insulin receptor 
substrate 1 (IRS-1) protein, which in turn activates phosphatidylinositol 3-kinase (PI3K). 
This activation enhances glucose transport and also affects the activation of nitric oxide 
(NO) production (113). Another route in insulin signaling is a mitogenactivated protein 
kinase (MAPK) pathway, in which there are mediated growth hormone properties of 
insulin, and which is involved in inflammation, cell proliferation and atherogenesis (113, 
114). In the insulin resistance state, the insulin signaling pathway is severely disturbed in 
the PI3K route but functions normally in the MAPK pathway (114). The latter pathway is 
over-stimulated by compensatory hyperinsulinemia and worsens the insulin resistance 
state (113).   
A defect of the endoplasmic reticulum (ER), the vast membranous network organelle 
responsible for protein metabolism, is also involved in insulin resistance (115). In ER 
stress, the situation which is created when newly synthesized unfold proteins accumulate 
in the ER in overabundance; a mechanism of unfolded protein response is activated. This 
mechanism is associated with inflammatory signaling systems, like the activation of 
inflammatory kinases, which results in an inhibition of insulin action. Reactive oxygen 
species (ROS), products of organelle stress, also impair insulin action and increase 
production of inflammatory cytokines (115). Thus ER stress leads to metabolic 
dysfunction. 
Insulin sensitivity and resistance is not a two-step condition, but instead a continuous 
process. When study subjects were divided into four groups according to fasting glucose 
levels (low-normal fasting glucose, high-normal fasting glucose, impaired fasting glucose 
(IFG), and combined impaired fasting glucose and impaired glucose tolerance (IGT)), it 
was found that insulin sensitivity is inversely related to glycemia, even within the normal 
fasting glucose range (116). Similarly, in a large study of 6414 Finnish men, insulin 
sensitivity was impaired already at relatively low glucose levels within the normal range 
of fasting glucose and 2-hour glucose levels (117). Additionally, a difference between IFG 
and IGT groups was found: compared to normal glucose tolerance, in isolated IFG both 
basal and total insulin releases were reduced, while in isolated IGT they were increased. 
This finding shows decreased insulin secretion to be a major defect in isolated IFG, while 
in isolated IGT the fault lies in peripheral insulin resistance (117). In earlier results 
concerning the site of insulin resistance, it was postulated that in IFG there is marked 
insulin resistance of the liver and milder resistance in peripheral tissues, but in IGT insulin 
resistance is just the opposite (118). These combined results suggest that at least partially 
different metabolic characteristics underlie IFG and IGT. In the glucose intolerance state, 
impaired insulin sensitivity is compensated with hyperinsulinemia, which is maintained 
with an increase in pancreatic β-cell mass, insulin synthesis and/or secretion (119). When 
this compensation fails, defects of insulin secretion become dominant because of 
glucolipotoxicity, the condition in which pancreatic β-cells are damaged due to excess 
concentrations of glucose and lipids, even though physiological levels of glucose and 
lipids are essential for normal β-cell function (6, 119).  
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Insulin resistance is an independent predictor of not only of T2D, but also hypertension 
and CVD (120). Though a natural consequence of obesity, insulin resistance does not affect 
all obese people; conversely, among obese subjects those with insulin resistance have a 
higher risk of CVD, compared to those without insulin resistance (120). Among newly 
diagnosed T2D subjects, there frequently appear signs of CVD (121). Subjects with T2D 
but without former myocardial infarction are known to share a similar risk of myocardial 
infarction, compared to subjects with former infarction but lacking T2D (122). Insulin 
resistance is speculated to act as a common link between obesity, CVD and T2D, possibly 
via low-grade inflammation (120, 123).  
2.2.2 Obesity 
During the last decades, an excess of body adiposity has become an epidemic, especially in 
Western countries. In the USA, the prevalence of being overweight (BMI ≥ 25 kg/m²) was 
72.3% among men and 64.1% among women, and the corresponding prevalence rates for 
obesity (BMI≥30 kg/m²) were 32.2% and 35.5%, respectively, according to NHANES 2007-
2008 data (124). Obesity prevalence in the U.S. has more than doubled in 25 years (from 
15% of obesity prevalence in 1980) (125). Excess weight gain is a global epidemic (126). In 
2008, according to the WHO estimation, there were 1.5 billion overweight adults in the 
world, of whom over 200 million men and nearly 300 million women were obese (127). In 
the National Finriski 2007 survey, among Finnish people aged 25-74 years, 66% of men 
and 52% of women were overweight (BMI≥ 25 kg/m²) and percentages of obesity (BMI≥30 
kg/m²) were 19% and 21%, respectively (128).  
Causes of weight gain are natural consequences of the westernized life style, with its 
excess of energy together with a sedentary lifestyle. These changes are a part of wide 
socio-economical alterations which have during the last ten to twenty years also affected 
developing countries where occupational structures have moved from agricultural work 
to industrial and service fields, motorized transport has developed, and household income 
has increased (126, 129). The underlying mechanisms of being overweight and obesity are 
only partially understood. They are complex and even controversial (129). Alterations of 
lifestyle probably explain obesity worldwide, but the cause of individual obesity is also 
involved with genetic factors (130). Obesity-associated diseases and metabolic 
disturbances are thus presumed to result from and be modified by gene-environment 
interaction (131). 
A person’s amount of body fat can be assessed with accurate methods, like measuring 
total body water or total body potassium, using bioelectrical impedance or dual-energy x-
ray absorptiometry. In particular, the degree of abdominal obesity is most accurately 
determined by using MRI or CT technology (132). However, these methods are expensive 
and hardly available in research work or clinical practice. Instead, a more practical 
approach for determining body fat and degree of obesity is to measure BMI, waist 
circumference or WHR; all are widely used in clinical work and in epidemiological 
research (132, 133). There is disagreement about the usefulness of these methods in risk 
assessment in relation to obesity-associated diseases, especially when there is increasing 
evidence about central and particularly visceral obesity associated with the risk of T2D 
and CVD (134, 135). However, there is a lot of documentation that by these simple 
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measurements it is possible to assess both body fat and its association with metabolic 
diseases in clinical practice (132, 136, 137). 
2.2.2.1 Fat distribution 
Since the first descriptions of the MetS, especially upper body adiposity has been found to 
be associated with this syndrome. Vague determined fat distribution with the brachio-
femoral fat ratio and named lower ratios as gynoid adiposity and higher ratios as android 
(male) type adiposity, firmly associated with metabolic consequences (39). In later 
research, fat distribution was divided into abdominal fat type, commonly seen in males, 
and peripheral fat type, in which fat is located in the gluteal-femoral region, as typically 
seen in women. Furthermore, with increasing volume fat seems to be stored equally in 
subcutaneous and visceral compartments in men, whilst in women increasing fat mass is 
first stored mainly in subcutaneous areas (138). Overweight men have been observed to 
have, even after body fat matching, a stronger risk profile for CVD than women; however, 
this difference seems to disappear among overweight women who have male-type 
abdominally distributed fat deposits (31). With CT scanning, it has been possible to further 
separate and divide centrally located fat into visceral and subcutaneous fat (139). In 
particular, visceral fat deposits contribute to insulin resistance and are associated with 
CVD risk and the MetS (28, 29, 30).  
All people with excess fat mass do not develop metabolically detrimental features 
(metabolically healthy obese subjects). Controversially, people have been identified with 
normal BMI but increased risk for the MetS, CVD and T2D (metabolically obese normal 
weight subjects) (140, 141). In obese people with metabolic disease, there has found to be 
more visceral fat compared to metabolically healthy obese individuals. Likewise, 
metabolically obese normal weight subjects usually have more visceral fat compared to 
subjects with similar weight but no metabolic disease (140, 141). Earlier results also show 
visceral fat depots, which account for less than 20% of total body fat at the most, to be 
metabolically the most active (142). Subcutaneous adipocytes are more sensitive to 
insulin’s antilipolytic effects and less sensitive to catecholamine-induced lipolysis than 
visceral adipocytes (143). Factors determining fat location are not thoroughly elucidated, 
but include the influence of sex hormones, glucocorticoids, genetic and also environmental 
factors (8, 144,145).The proportion of visceral fat increases with age and in women with 
menopause (146,147). Though subcutaneous adipose tissue may not have as detrimental a 
role as visceral fat in the development of the MetS, and has even been considered 
beneficial in context of the MetS, excessive subcutaneous fat also needs to be considered as 
pathogenic (8, 148).   
Additionally, there is evidence that both a lack and an excess of adipose tissue can 
emphasize metabolic disturbances. In lipodystrophy syndromes, states with decreased 
amounts of both subcutaneous and visceral fat, there is a strong association between 
insulin resistance, hyperglycemia, dyslipidemia and fatty liver (149). Without sufficient 
adipose tissue, FFAs are not stored adequately and may thus accumulate in muscle and 
the liver, which causes insulin resistance in these organs and may also lead to lipotoxicity 
(150). On the other hand, with an excess of body fat there may also appear a deficiency in 
fat storage in adipose tissue (149). The hypothesis of adipose tissue expandability is 
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presumed to answer this controversial situation: the metabolic consequences of an 
individual are dependent on, instead of the total amount of adipose tissue, the capability 
of adipose tissue to expand to store lipids (148). At the point where adipose tissue 
expansion is no longer possible, metabolic disturbances appear with fat accumulation in 
non-adipose tissue like liver, muscle and pancreatic β-cells. In these ectopic sites, lipids are 
thought to cause insulin resistance in a lipid-induced toxic way, thus sharing the same 
kind of mechanism of lipotoxicity, regardless of amount of adipose tissue (148, 150). There 
is support to this theory in an animal model with ob/ob mice, in which a vast increase in 
degree of obesity did not impair insulin sensitivity nor cause fat accumulation in the liver, 
but instead an increase in subcutaneous adipose tissue was associated with remarkable 
metabolic improvement in these mice (151). In humans as well, this theory receives 
support with evidence that larger subcutaneous adipocytes are associated with the 
development of T2D and, more recently, from studies which show that thiazolidinedione 
insulin sensitizers (TZD), in spite of weight gain, improve insulin sensitivity and reduce 
fat accumulation in the liver (152,153). Thus adipocytes are, with enlargement, thought to 
lose their efficiency as metabolic buffers. This phenomenon lets non-adipose tissues be 
exposed to excessive fluxes of lipid fuels, leading to insulin resistance in extra-adipose 
tissues, like liver and skeletal muscle. TZDs are speculated to stimulate adipocyte 
differentiation and to create new smaller adipocytes with lipid-buffering capability, thus 
diminishing insulin resistance (154).  
The location of visceral fat in the abdominal cavity enhances the flux of FFAs to the 
liver (portal theory), but more recent research has proven visceral and peripheral adipose 
tissue to be distinct also in genetic issues (155). On the other hand, genetic research results 
are also contradictory (156). Further research of the reasons and effects of fat distribution 
regarding the MetS is lively and ongoing and definitely needed to construct a coherent 
overview. 
2.2.3 Low-grade inflammation in the development of the metabolic syndrome 
With increasing knowledge of adipose tissue as an endocrine and immune organ, rather 
than just a store of energy, there have appeared new aspects regarding the role of this 
tissue in the development of the MetS. In addition to adipocytes, which form 
approximately 50% of the cellular content of adipose tissue, this tissue consists of 
macrophages, endothelial cells, pre-adipocytes, nerve tissue, connective tissue matrix, 
leucocytes and fibroblasts (8, 14, 157). Adipose tissue secretes several cytokines which 
have anti- or pro-inflammatory effects (8). Cytokines produced mainly, though not solely, 
by adipose tissue are called adipocytokines. These proteins act as soluble mediators and 
regulators in multiple endocrine functions. Noticeably, not all cytokines (even though they 
may partly be produced by adipocytes) are called adipocytokines; however, there are 
contradictions in terminology regarding this issue (7, 14, 92).  
Adipose tissue excess, particularly viscerally located, is firmly associated with the pro-
inflammatory state (88). There is a large body of research evidence proving that adipose 
tissue depots differ in the degree of metabolic properties with enhanced activity in visceral 
adipose tissue compared to subcutaneous adipose tissue (142,158). Additional evidence 
suggests that subcutaneous adipose tissue in the abdominal region probably differs from 
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peripheral subcutaneous adipose tissue with higher metabolic activity (e.g. increased 
production of inflammatory cytokines), though it does not reach as high activity as 
visceral adipose depot (159). Along with cytokines, synthesis of other inflammatory 
markers, like C-reactive protein (CRP), is increased in obesity and insulin resistance (14). 
There appears to be growing evidence concerning the association between the MetS and 
low-grade inflammation (160, 161). This association is supported by both decreased levels 
of anti-inflammatory cytokines and increased levels of pro-inflammatory cytokines 
present with the MetS (161, 162, 163). The adipocytokines adiponectin and leptin, 
chemokines tumor necrosis factor-α (TNF-α) and IL-6 are most frequently associated with 
insulin resistance (14). 
2.2.3.1 Adiponectin 
Adiponectin was first described approximately 15 years ago. This protein is secreted 
mainly by adipose tissue, but it is also produced by myocytes, both in skeletal and in 
cardiac muscles; it is also present in bone marrow (164, 165). Adiponectin is expressed 
more in subcutaneous, than in visceral adipose tissue compartment (8).  It has been named 
with several terms like adipocyte complement-related protein of 30 kilodalton (Acrp30), 
AdipoQ and gelatin-binding protein of 28-kilodalton (GBP28). The term adiponectin, 
however, is an established one (8, 166). Two adiponectin receptors have been identified: 
AdipoR1, which is widely expressed in muscle, and AdipoR2, which is present mainly in 
the liver (8, 167). 
Adiponectin concentrations in human plasma are between 5 to 30 μg/ml in lean 
subjects, and concentrations are higher in women than in men (166). On the contrary, 
compared to other adipocytokines, adiponectin concentrations are lower in obese subjects 
than in non-obese subjects; furthermore, concentrations are inversely associated with the 
amount of visceral adipose tissue (166, 168). Additionally, plasma adiponectin levels 
decrease with insulin resistance, T2D and ischemic heart disease (166,168,169,170). 
Decreased adiponectin concentrations are also associated with elevated plasma 
triglyceride and decreased plasma HDL-cholesterol levels (11, 171). In hypertension, there 
exist low adiponectin levels as well (10, 172). Thus, the classical components of the MetS 
are involved with hypoadiponectinemia, which has even been suggested as a potential 
additional component of the MetS by some researchers (12, 13). Adiponectin concentration 
also decreases with an increase in the number of components of the MetS (12). 
Adiponectin may act as a promoter in the network of pro- and anti-inflammatory 
cytokines; with decreased synthesis of adiponectin, the control mechanisms of the 
production of many pro- and anti-inflammatory cytokines are probably inhibited (14). 
Adiponectin is capable of suppressing the reactions caused by TNF, which has even been 
considered as its main anti-inflammatory function, and it enhances the production of anti-
inflammatory cytokines like interleukin-10 and interleukin-1 receptor antagonist (IL-1Ra) 
(14). 
In studies of Pima Indians, in whom there is expressed a high prevalence of obesity and 
T2D, individuals with higher adiponectin levels had a lower risk of diabetes in 
longitudinal studies (173). Furthermore, neither low waist circumference nor low fasting 
glucose was as protective as higher adiponectin levels as regards the risk of T2D (173). 
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Independently of traditional risk factors, higher adiponectin levels were also associated 
with lower myocardial infarction risk in men in a prospective follow-up study of six years 
(174). Later research has observed positive associations between lower adiponectin 
concentrations and obesity-related malignancies (like breast, prostate, endometrial and 
colon cancers) (175). Thus, multiple studies refer to the protective role of adiponectin in 
several diseases, but the functional mechanisms behind it are not totally understood. 
Adiponectin circulates in blood in three main forms: trimer, hexamer and high-
molecular weight form, with the latter putatively being the most insulin-sensitizing (92). 
Adiponectin increases fatty acid oxidation and glucose uptake in muscle and reduces 
gluconeogenesis in the liver; these effects are partly mediated through activation of AMP-
activated protein kinase (AMPK) (176). Furthermore, research results with mice showed 
that adiponectin elevates plasma insulin levels when injected intravenously (177). 
Adiponectin concentration is inversely associated with weight gain. In obesity, 
adiponectin receptors are also down-regulated; however, these changes are restored with 
weight loss (178). Additionally, adiponectin concentrations have been found to rise with 
exercise and also with dietary intake of linoleic or omega-3 fatty acids (179, 180). With 
smoking there emerges a decrease in adiponectin levels, even dose-dependently (181). 
Intake of certain drugs like fenofibrates, statins, angiotensin-converting enzymes (ACE) 
inhibitors and TZDs are associated with elevated adiponectin concentration (182, 183). The 
physiological mechanisms behind the changes of adiponectin concentration are not 
elucidated and the research results concerning these issues are ambiguous. The challenge 
is to find out the mechanism of adiponectin decrease with weight gain. This finding would 
probably lead to a better understanding of the whole cytokine network. 
2.2.3.2 Interleukin 1-β and Interleukin 1-receptor antagonist 
Interleukin-1 (IL-1) was first described with studies concerning the endogenous mediators 
of fever (184). IL-1, which is referred to as a prototypic pro-inflammatory cytokine, 
consists of two distinct ligands, interleukin 1-alpha (IL-1α) and interleukin 1-beta (IL-1β), 
both of which are synthesized as large precursor proteins (185). Though first isolated from 
leukocytes, interleukins are secreted from several non-leukocytic cells and also from 
adipose tissue (8, 17, 184). There exist two primary receptors for IL-1α and IL-1β, with a 
type I receptor being responsible for most IL-1 mediated actions (185). Within the IL-1 
family, there also appears a natural antagonist for IL-1α and IL-1β, the IL-1 receptor 
antagonist (IL-1Ra). This anti-inflammatory member of the IL-1 group is produced by the 
same cells as IL-1α and IL-1β and competitively binds to the IL-1 type I receptor, thus 
preventing IL-1 signaling (185). Later research has revealed other members of the IL-1 
family, and this expansion has led to new nomenclature. Also IL-1β and IL-1Ra have new 
systemic names (IL-1F2 and IL-1F3, respectively), but the names first mentioned are still 
widely used in research (186). 
Elevated levels of IL-1β and IL-1Ra have been detected in subjects with essential 
hypertension and with atherosclerosis (15, 16, 17, 187). In the development of type 1 
diabetes, IL-1β has been demonstrated to mediate impairment of the function of pancreatic 
β-cells (188). IL-1β even inducts apoptosis in human Langerhans islets (189).  Furthermore, 
a high concentration of glucose has been shown to induce the production and secretion of 
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IL-1β in human pancreatic β-cells. According to this finding, there have been suggestions 
that IL-1β might be involved in the pathogenesis of T2D as well (190). IL-1Ra, as expected 
of an IL-1 antagonist, seems to protect pancreatic β-cells from glucose-induced impairment 
and apoptosis (190). On the other hand, there is controversy in the research, with some 
results showing that high glucose does not induce IL-1β production in pancreatic islets 
and the mechanism of β-cell death is different in type 1 diabetes, compared to β-cell death 
in T2D (191). Decreased levels of IL-1Ra have been reported with T2D patients, whereas 
elevated IL-1Ra levels have been detected in insulin resistance and obesity and precede the 
onset of T2D (18, 192, 193, 194). In the pre-diabetic state, an increase in IL-1Ra levels has 
been shown to be the most sensitive marker for cytokine response (19).  Also with the 
MetS, the levels of IL-1Ra seem to correlate positively (18, 195). 
Levels of IL-1β are usually not elevated in the circulation of healthy individuals in 
contrast to IL-1Ra, which is constantly present (16,185). In unstable coronary arterial 
disease, there appears an elevated level of IL-1β but no corresponding elevation of IL-1Ra 
levels, which points to inflammatory dominance (196). A low IL-1Ra/IL-1β ratio is present 
with newly diagnosed insulin dependent diabetes mellitus. This ratio, however, seems to 
return to normal values with the chronic diabetes (197). On the other hand, in knee 
osteoarthritis the IL-1Ra/IL-1β ratio was found to be highly elevated (198). As far back as 
two decades ago, it was demonstrated that a 10- to 100-fold excess of IL-1Ra over IL-1β 
suffices to block the effects of IL-1β on pancreatic islets (199). There is growing evidence 
that pro- and inflammatory cytokines function in a tight connection. For example, 
adiponectin is known to be capable of inducing the production of IL-1Ra and suppressing 
several inflammatory cytokines (14, 167). However, the mechanisms behind the activation 
of the innate immune system, which affects the levels of pro- and anti-inflammatory 
cytokines or their reciprocal balance, are not fully understood, not even between IL-1β and 
its natural antagonist IL-1Ra. 
2.2.3.3 C-reactive protein 
C-reactive protein (CRP) is a first described acute phase reactant and an indicator of 
systemic inflammation or inflammatory condition, e.g. tissue damage by cancer or trauma 
(200). CRP concentration is determined by genetic factors, but in particular centrally 
located adiposity is considered to be a major determinant of CRP levels (25). Synthesis of 
CRP is occurring in hepatocytes and it is stimulated by IL-1 and IL-6 (23). There is also 
some evidence that CRP would be synthesized in some other cells, like in macrophages 
within atherosclerotic lesions; these results, however, have been contradicted by later 
studies (201, 202). However, when adipocytes isolated from human adipose tissue were 
incubated with inflammatory cytokines IL-1β and IL-6, CRP production was seen in these 
adipocytes (203). CRP concentrations in healthy subjects are from around 1 mg/l to less 
than 10 mg/l, but in acute phase response the concentration can rapidly increase to the 
level of 400 mg/l (204). With high-sensitivity CRP (hs-CRP), one is referred to newer 
immunoassay methods with a sufficient sensitivity to measure CRP through the normal 
range (and even below 1 mg/l), instead of less sensitive standard assays; hs-CRP is not a 
novel protein. 
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Three decades ago, it was demonstrated that CRP binds specifically to LDL and VLDL 
(205). Elevated CRP levels have been detected to correlate positively with BMI, with 
insulin resistance measured by HOMA, and negatively with HDL levels (206). Among 
hypertensive subjects, CRP concentrations are often elevated (21). With increasing 
knowledge of inflammation as an important factor in cardiovascular diseases that is also 
associated with the MetS, the question has arisen of a possible role of CRP in the 
atherosclerotic process (207, 208, 209). Among initially healthy middle-aged men, a strong 
relationship was demonstrated between CRP levels and the future risk of a coronary 
event, even with low levels of CRP (210). Among middle -aged women as well, the level of 
CRP was found to be the most powerful predictor of the risk of a future cardiovascular 
event, even in women with low cholesterol levels (211). On the other hand, among a large 
Reykjavik Study population, even though CRP levels were found to be stable from decade 
to decade and thus a usable risk predictor, they were only a relatively moderate predictor 
of future cardiovascular risk. Furthermore, CRP levels (compared to established 
traditional risk factors) could not add predictive value, except very marginally (212). 
In the study concerning associations between CRP and the features of the MetS, there 
was found to be a positive correlation between CRP and diabetes, uric acid and BMI, with 
the strongest correlation between CRP and BMI (213). Additionally, CRP levels were 
found to increase with the number of the components of the MetS (213). According to 
some researchers, CRP has even been suggested as an optional component of the MetS 
(14,214,215). CRP levels of >3mg/L were found to add prognostic information at all levels 
of severity of the MetS in the assessment of future cardiovascular risk (216). This cut-off 
point is in line with the recommendation of the Centers of Disease Control and Prevention 
/AHA Statement, in which the risk for cardiovascular disease has been classified according 
to CRP-levels as follows: low risk = CRP<1mg/L; average risk = 1.0mg/L<CRP<3.0mg/L; 
and high risk = CRP>3 mg/L (217). In a Japanese study, the cut-off point of hs-CRP for the 
MetS was recommended to be 0.65 mg/l (218).  
It is still unclear whether CRP is just a marker or an active participant of an 
inflammatory process. There is, however, evidence, that measurement of CRP may be 
useful in early prediction of future diabetes and cardiovascular risk, also among subjects 
with the MetS (215). Furthermore, hs-CRP is capable of providing further information 
about the MetS because of its strong connection with those MetS components which are 
difficult to measure, like fibrinolysis and insulin resistance (214, 219). These arguments, 
taken together with the fact that traditional risk factors are lacking in every fifth case of 
coronary heart disease, reflects the need for other risk factors. CRP is a potential candidate 
to fulfill this demand, especially with its currently inexpensive cost (220). 
2.2.3.4 Other inflammatory markers associating with the metabolic syndrome 
TNF-α is considered as a first pro-inflammatory link between obesity and insulin 
resistance (221). It is produced mainly by macrophages and lymphocytes, but only in 
lesser concentrations from human adipocyte, which has led to the idea that elevated TNF-
α levels seen in obesity are probably not regulated by adipose tissue (92). However, TNF-α 
levels are positively associated with fasting insulin, waist circumference, and triglycerides 
and negatively with HDL-levels. Furthermore, TNF-α concentration increases in parallel 
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to the number of the MetS components (222).The synthesis of TNF-α is suppressed by 
adiponectin (14).  
Leptin, a pro-inflammatory cytokine produced mainly by adipocytes, is known to 
control appetite. It is secreted mainly by subcutaneous adipose tissue and its concentration 
correlates positively with the percentage of body fat (223). Initially leptin was thought to 
decrease food intake and weight gain in brain level, but there have been later observations 
according to which decreased leptin levels after weight loss signal the hypothalamus to 
reduce energy expenditures and to increase feeding to regain weight (224). These 
observations have led to the hypothesis that by inhibiting declines in leptin levels during 
weight gain, it would be possible to maintain weight loss (224). This hypothesis is 
supported by results in mice where leptin increased the effect of sibutramin by increasing 
fatty acid oxidation and decreasing food intake (225). Leptin levels have been found to 
predict the development of the MetS, independently of obesity (226). 
IL-6 is secreted from adipose tissue, with higher levels from visceral than subcutaneous 
compartments (221). IL-6 is known to induce the hepatic production of CRP and is thus 
related to elevated CV risk. Moreover, due to direct drainage from visceral adipose tissue 
to the portal vein, it has been speculated that IL-6 levels contribute to hepatic metabolism 
by enhancing VLDL secretion and hypertriglyceridemia (227). Elevated IL-6 levels are also 
strongly associated with decreased insulin sensitivity (227). 
In addition to the abovementioned cytokines, there are several other ones (like resistin, 
visfatin and plasminogen activator inhibitor-1, together with the more recently discovered 
vaspin and omentin), all of which contribute to the development of insulin resistance (14, 
92). The network of these cytokines, which are mainly secreted by adipose tissue, is 
complex. Although actively being researched, they are still insufficiently understood. That 
said, they are charged with expectations as a potential link in the missing connections 
between obesity, inflammation and the MetS. 
2.3 HYPERTENSION, LOW-GRADE INFLAMMATION AND THE 
METABOLIC SYNDROME 
Elevated blood pressure is associated with insulin resistance or hyperinsulinemia 
(228,229). Intravenously administered insulin reduces urinary sodium excretion when 
given to subjects of normal weight (230). Insulin resistance is associated with increased 
sodium reabsorption, but also with impaired vasodilatation, which could be one potential 
reason for the development of hypertension in the insulin resistant state (231, 232). 
Low-grade inflammation has been presumed to be an independent risk factor for 
hypertension (233). In essential hypertension, there appear decreased adiponectin 
concentrations as well as elevated levels of IL-1β and IL-1Ra, IL-6 and TNF-α, for example. 
Furthermore, CRP levels are increased (9, 15, 16, 17, 233). Hypoadiponectinemia has been 
speculated to have a role in the pathogenesis of hypertension, probably via insulin 
resistance but also through activation of the inflammatory network and endothelial 
dysfunction (234). Moreover, a decrease in adiponectin levels may increase vascular 
smooth muscle proliferation, leading to arterial stiffness (234). The idea that low-grade 
inflammation impairs endothelial function is supported by findings that by causing 
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inflammation with Salmonella typhi vaccination, IL-6 levels are elevated and, moreover, 
there emerges a strong resistance to vasodilating stimuli in vessels (235). Thus a possible 
mechanism between low-grade inflammation and hypertension could be due to an 
imbalance between vasodilating and vasoconstricting factors; low-grade inflammation 
may have an effect on the synthesis and degradation of these substrates, with nitric oxide 
being one possible target (233). In hypertensive (but not in normotensive) rats, there has 
been shown a direct vasoconstriction caused by IL-1β; furthermore, IL-1β enhanced the 
vasoconstriction effect of phenylephrine (236).  
The MetS has been shown to predict CVD events in hypertensive subjects 
independently of traditional risk factors (237). In hypertensive subjects, the MetS impairs 
total arterial compliance (238). Particularly, in untreated hypertension the MetS is 
associated independently with aortic stiffness, which was found to also be determined by 
central obesity, but not by BMI (239). When hypertensive subjects with and without the 
MetS were compared in relation to cardiovascular damage, this damage was statistically 
more frequent among the MetS group and, moreover, strongly related to increased low-
grade inflammation and fibrosis present in this group (240). There is, therefore, increasing 
data that low-grade inflammation is connected with hypertension when the MetS is 
present. 
2.4 DYSLIPIDEMIA, LOW-GRADE INFLAMMATION AND THE METABOLIC 
SYNDROME 
Elevated triglycerides and decreased HDL-levels, the characteristic dyslipidemic factors of 
the MetS, are associated with low-grade inflammation (241, 242). IL-6 is capable of acting 
as an independent stimulator of triglycerides in the liver in animal models (243). 
Hypertriglyceridemia is associated with decreased adiponectin levels, even when it is 
present without the MetS (244). The liver is the main source of lipid regulation in the body 
and abundant fat accumulation in the liver is considered as a hepatic sign of the MetS 
(245). Of liver fat, 60% comes from non-esterified fatty acids, which are a result of lipolysis 
in adipose tissue or are hydrolyzed from lipoproteins at such a rate that they cannot be 
assimilated by adipose tissue, 25% comes from newly synthesized fatty acids and 15% 
comes from dietary chylomicrons (245). Non-alcoholic fatty liver disease (NAFLD) is 
strongly associated with obesity and insulin resistance; it has been observed that 70% of 
subjects with T2D, and even 95 % of those who are obese, have NAFLD (246). NAFLD is a 
strong predictor of the MetS, even in non-obese, non-diabetic subjects, and it can thus be 
considered an early sign of the MetS (247). In subjects with the MetS, the incidence of 
NAFLD is fourfold in men and 11-fold in women, compared to subjects without the MetS 
(248). The amount of fat accumulated in the liver is correlated with the quantity of visceral 
adipose tissue and with insulin resistance. In the insulin resistance state, increased hepatic 
triglyceride synthesis may result in the synthesis of very low-density lipoproteins (VLDL), 
which form highly atherogenic small dense lipoprotein particles, cholesterol-rich VLDL 
remnants and triglyceride-rich HDL particles (249). These HDL particles may be cleared in 
the kidneys, thus leading to decreased HDL levels (250). Thus, dyslipidemic features that 
are characteristic of the MetS are seen in NAFLD. Also adiponectin levels are decreased in 
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NAFLD. Furthermore, in experimental models there appears an amelioration of NAFLD 
with administration of adiponectin (251). In the case of low-grade inflammation, fat 
accumulation in the liver, insulin resistance and the MetS, there is no straight or direct 
causality but instead a complex network of probably genetic and as yet unknown factors 
which contribute to each other, making a dynamic continuing process (246). NAFLD is, 
however, closely related to the MetS and might be even a central factor in the 
pathophysiology of the dyslipidemia frequently seen in the MetS.  
2.5 OTHER CONDITIONS ASSOCIATED WITH THE METABOLIC 
SYNDROME 
There are several conditions which are associated with the MetS, even though they are not 
included in the diagnostic criteria of this syndrome. In addition to the previously 
mentioned NAFLD, there is evidence that polycystic ovarian syndrome (PCOS), 
hypogonadism, obstructive sleep apnea, prothrombotic state, hyperuricemia, depression 
and Alzheimer’s disease are also associated with the MetS. Among subjects with metabolic 
disorders, there are observed cancers of reproductive and gastrointestinal systems more 
often than in the general population (252).  
PCOS is accompanied with increased T2D risk as well, with increased risk for CV risk 
factors (253,254). Hyperinsulinemia has been speculated to be a common pathogenetic 
factor behind PCOS, with which the MetS commonly appears (255). Furthermore, 
increased visceral adipose tissue has been observed in PCOS and inflammatory cytokines 
seem to stimulate androgen production of ovaries affected by PCOS (256). Though further 
research is definitely needed, there is significant evidence suggesting that PCOS might 
occur in conjunction with the MetS. 
Hypogonadism is associated with the MetS and T2D (257). In men who were unaware 
of their hormone concentrations, low levels of testosterone as well as sex-hormone binding 
globulin were independent risk factors for the development of the MetS (258). In 
particular, visceral adiposity appears together with hypogonadism (259). Furthermore, 
there is evidence showing that features of the MetS may be ameliorated and levels of the 
pro-inflammatory cytokines may be decreased with testosterone replacement therapy (260, 
261). 
Obstructive sleep apnea is firmly connected with obesity. Similarly, there is an 
association between obstructive sleep apnea and insulin resistance, as well as increased 
levels of inflammatory markers. The prevalence of the MetS is high among subjects with 
this disorder (262, 263).  
Recently several groups have reported their findings about the associations between 
carcinogenesis, the MetS, visceral adiposity and insulin resistance (264, 265, 266). 
Furthermore, there are results suggesting that both visceral adiposity and the MetS might 
be associated with more progressive tumors and reduced survival (265, 266). 
The underlying pathological mechanisms connecting these conditions which have been 
reported to be associated with the MetS are not simple nor solved. Inflammatory aspects 
and especially visceral adiposity are thought to be important contributors in this network 
of several diseases. However, much additional knowledge is needed before there is solid 
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proof of these connections and even more before it will be possible to solve the multiple 
pathways which mediate these associations. 
2.6 SMOKING IN RELATION TO THE METABOLIC SYNDROME AND LOW-
GRADE INFLAMMATION 
Smoking is a well known risk factor for CVD. Smoking is also correlated with insulin 
resistance and the MetS, and smokers seem to be at increased risk of T2D (26,267- 271). 
With smoking, the risk for complications of diabetes (such as neuro-, nephro- and 
retinopathy) increases as well (269). Smoking has harmful effects on body fat distribution 
with increased centrally located fat, even dose-dependently (272, 273).  Furthermore, there 
is evidence that smoking is positively associated with the increase of total body fat (273). 
Increased levels of inflammatory markers have been observed in smokers, even though in 
studies concerning acute smoking there has also been found suppression of inflammatory 
cytokines (274, 275). Moreover, among smokers, adiponectin levels are shown to be 
decreased (181, 276, 277). Additionally, there are results that suggest that adiponectin 
levels are elevated and pro-inflammatory markers decrease with smoking cessation (278 -
281). However, levels of CRP have been found to be significantly elevated among ex-
smokers even 10 to 20 years after quitting, which may suggest ongoing low-grade 
inflammation in these former smokers (27). 
The association between smoking and body weight is complicated. Smokers often seem 
to have lower body weight compared to non-smokers (272, 282). However, there are 
results from a male study population that show waist circumference being relatively larger 
and hip circumference smaller in smokers, compared to non-smokers (272). Furthermore, 
with smoking cessation and subsequent weight gain, the increase in WHR is not as large 
as expected given the added weight, thus indicating that fat in smokers probably is more 
centrally located (272). Additionally, that finding leads to speculation that smokers not 
only have increased abdominal fat, but also probably lose muscle (272). In another study 
conducted among the Swiss population, an increase in waist circumference was found in 
both genders who smoked. Moreover, smokers had more total body fat compared to non-
smokers; this finding was especially pronounced in females (273). 
Estrogen levels are lower in female smokers (283). With estrogen decrease during 
menopause, there appears an increase in visceral fat mass (284, 285). Thus, smoking is 
thought to contribute to an accumulation of centrally located fat via estrogen; this could 
partly explain the harmful association of visceral fat with smoking in females (284). In 
males, there are similar findings of lower levels of testosterone, as appears with aging, 
being associated with more centrally accumulated fat (286). Smokers have higher levels of 
cortisols. Interestingly, between active and passive smokers there were not found any 
differences in steroid hormones (287,288, 289). Cortisol levels are also known to influence 
central fat accumulation (290). Smoking is often accompanied with other deleterious habits 
like physical inactivity, alcohol consumption and unhealthy diet, which may contribute to 
a degree of obesity (291). With growing evidence that increases in both total body fat and 
centrally located fat accelerate low-grade inflammation, it seems definitive that the 
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deleterious effects of smoking are mediated partly through inflammatory changes. Still, 
further research is needed to determine the causal pathways.  
2.7 THE ROLE OF GENDER IN METABOLIC DISEASES 
Though men are known to be at greater risk of CVD compared to women in the general 
population, it seems to be totally the opposite case among diabetic subjects. As a result of a 
large Australian meta-analysis, there was observed to be a 50% higher relative risk of fatal 
coronary heart disease in diabetic women than in men (292). There are similar results in 
several studies where diabetic women seem to be at higher risk of major as well as all CVD 
events, compared to diabetic men, even to the extent that the gender-related advantage in 
non-diabetic women compared to non-diabetic men seems to be completely lost (35,36). 
The MetS appears to be a stronger predictor of CVD in women than in men (32). The effect 
of the MetS on left ventricular function and hypertrophy is greater in women than in men 
among hypertensive subjects (33). In the Hoorn Study, it was observed that impaired 
glucose tolerance and T2D are associated with increased left ventricular mass in women, 
but not in men (293). 
CRP levels seem to be a better predictor of T2D in women than in men (34, 294). In 
another study, a similar gender difference between CRP and early progression of carotid 
atherosclerosis was found (295). In subjects with T2D, both leptin and IL-1Ra levels were 
significantly elevated in women, compared to men (296). Adiponectin concentrations in 
healthy subjects are constantly higher in women than in men (166). This development in 
adiponectin concentrations seems to begin in childhood, with increasing difference after 
the progression of puberty in boys (297). Furthermore, lower adiponectin levels were also 
found in obese children, compared to normal weight children, in relation to the degree of 
obesity (297). Hypoadiponectinemia has been linked with obesity, T2D and CVD. Because 
of evidence that adiponectin levels decrease with increased abdominal obesity, changes in 
fat distribution have been suggested as an explanation for the gender differences 
regarding these diseases and adiponectin, and probably also wider low-grade 
inflammation (166, 168).  
The observation that CVD begins to appear relatively more in women in menopause, 
and the well-known fact that women have similar CVD prevalence rates as men around 
ten years greater in age, has led to the idea that estrogen provides protection for women 
against metabolic diseases (60,298, 299). These ideas could also be supported by changes in 
fat distribution with aging, while decreases in estrogen levels are associated with centrally 
located fat (284, 285). In the Health in Men Study, low testosterone levels were found to 
predict CVD mortality (300). Similar results were found also in meta-analyses of 70 
studies. Furthermore, testosterone replacement therapy has been useful in reducing risks 
of CVD (301). However, it is not possible to present any causality in the involvement of sex 
steroid hormones and metabolic diseases until further research has been done.  
In any case, it seems clear that there are gender-specific risks for CVD and other 
metabolic diseases. Continuous further research is warranted to solve problems, especially 
including women’s heart disease diagnosis and treatment; thus far, there are still several 
unsolved problems in this question of gender differences in metabolic diseases (302, 303). 
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2.8 CONTROVERSIES REGARDING THE METABOLIC SYNDROME 
As mentioned above, there exist several theories with unanswered questions about the 
pathophysiology of the MetS. Uniform criteria for the MetS are still under debate and the 
different definitions identify different individuals as having the MetS (78). Moreover, there 
is disagreement about the usefulness of this cluster in predicting the risk for CVD or T2D, 
especially compared to established predictive scores like Diabetes Risk Score (5, 304),   
These issues have raised criticism about the term “syndrome”, which refers to unified 
pathophysiology and the MetS to be a special “diagnosis”, especially when the treatment 
of this syndrome is nothing else but the treatment of its components (305).  The debate 
about the existence of the MetS is ongoing, with statements for and against it (89, 305, 306, 
307). At the same time, with the current epidemic of obesity, there is a great need for better 
tools to identify individuals with increased risk of CVD and T2D.  
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3 Aims of the study 
The aim of this study was to obtain new, gender-specific information about the association 
of adiponectin and low-grade inflammation with factors that often precede the metabolic 
syndrome and to get information about these markers in relation to the course of the 
metabolic syndrome. 
 
More specifically, this study was intended to address the following objectives: 
 
1. To study possible gender differences in adiponectin and markers of low-grade 
inflammation within a relative change of BMI from youth to middle-age. 
 
2. To examine from a gender-specific point of view the associations between 
smoking and low-grade inflammation measured by adiponectin and hs-CRP. 
 
3. To investigate gender differences as related to low-grade inflammation and 
insulin resistance in hypertensive subjects with the metabolic syndrome. 
 
4. To study the associations between adiponectin and low-grade inflammation in 
relation to the course of the metabolic syndrome, and to assess gender 
differences related to this question.  
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4 Subjects and methods 
4.1 STUDY POPULATION 
All inhabitants of the town of Pieksämäki born in 1942, 1947, 1952, 1957 and 1962 (n=1294), 
without any excluding criteria, were invited for a health check-up during the years 1997-
1998 and again in the years 2003-2004. Written invitations were mailed according to the 
civil register and repeated two separate times. Of all invited subjects, 923 (71.3%, 411 men 
and 512 women) participated in the first health check-up, and 681 subjects of them 
participated in the second check-up. The study population is presented by gender and 
year of birth in Figure 2. 
  
 
 
  
Figure 2. Study population (n=923) by year of birth and gender 
 
  
 
In Study I, from the first check-up, 18 subjects of 923 with possible acute inflammatory 
condition (hs-CRP ≥ 10 pg/ml) and two subjects with missing weight information as a 
youth were excluded. Thus, the final study population consisted of 903 subjects (403 men 
and 500 women). 
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In Study II, of the 923 subjects in the first check-up, 64 diabetic subjects as well as 18 
subjects (7 men, 11 women) with hs-CRP ≥ 10 pg/ milliliter, who might therefore had some 
acute inflammatory condition, were excluded. The final non-diabetic study population 
consisted of 841 subjects (365 men and 476 women). 
In Study III, all subjects from the first check-up with systolic blood pressure ≥ 130 
mmHg or diastolic blood pressure ≥ 85 mmHg or receiving antihypertensive medication 
were included, while subjects with hs-CRP  ≥  10 pg/ml (n=18) were excluded, due to 
possible acute inflammatory condition. Thus, the final study population included 551 
subjects (278 men and 273 women).  
In Study IV, the study population consisted of 680 subjects (284 men and 396 women) 
who participated in both check- ups (n=681), except one subject with hs-CRP ≥ 30 pg/ml, 
who probably had some acute inflammatory condition. Both male and female subjects 
were divided into four groups, according to their MetS status at the first and second 
check-ups: “No MetS” (= subjects who did not have MetS at either point of measurement), 
“Incident MetS” (= subjects who did not have MetS at the first point of measurement but 
in whom it was expressed at the second point of measurement), “Persistent MetS” (= 
subjects who had MetS both at the first and the second point of measurement), and 
“Resolute MetS” (= subjects who had MetS at the first point of measurement but not at the 
second one). 
4.2 CLINICAL METHODS, QUESTIONNAIRES AND INTERVIEWS  
All subjects completed a questionnaire about their medical history and their current 
medical condition. They were interviewed and examined by a nurse who was specially 
trained for this task by a researcher physician in 1997. 
Subjects were asked about their smoking habits, alcohol consumption and physical 
activity. Subjects who smoked on a daily basis were considered to be current smokers. All 
subjects who used alcohol, regardless of amount, were considered to be alcohol users. 
Subjects exercising at least three times a week with a minimum of 30 minutes a session 
were considered to be physically active.  
Subjects were also asked about their height and weight at the age of 20 years, as well as 
the length and degree of their education. Total education of ≤ 10 years was referred to as 
“lower education” and thus lower socio-economical status in Study I. 
Weight while wearing light clothing and height were measured to an accuracy of 0.1 kg 
and 0.5 cm, respectively. Body mass index (BMI) was calculated as weight (kg) divided by 
height (m) squared. The relative change in BMI (Study I) was calculated as the BMI at the 
check-up divided by BMI at the age of 20 years. Waist circumference was measured from 
the midpoint between the lateral iliac crest and the lowest rib to an accuracy of 0.5 cm.  
Blood pressure (BP) was measured with a mercury sphygmomanometer, after the 
subject had 15 minutes of rest, in a sitting position. The measurement was repeated after 
five minutes. The mean of the two measurements was used in the analyses, except in 
Study II where the second reading was used in analyses. 
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4.3 LABORATORY MEASUREMENTS AND CALCULATIONS 
Fresh blood samples were drawn after an overnight (12 hours) fast. Plasma was separated 
by centrifugation for the determination of fasting insulin, and the samples were frozen 
immediately to -20 . The frozen samples were transported weekly to Kuopio University 
Hospital and stored at -70  until adiponectin, interleukin-1 receptor antagonist (IL-1Ra), 
interleukin-1β (IL-1β) and high-sensitivity C-reactive protein (hs-CRP) were analyzed in 
2003, contemporaneously in the scientific laboratory of the University of Kuopio. 
Plasma insulin was determined using the Phadesph Insulin radioimmunoassay (RIA) 
100 method (Pharmacia Diagnostics AB, Uppsala, Sweden) in the scientific laboratory of 
Kuopio University Hospital. 
Plasma glucose concentration was measured by an automated colorimetric method 
(Peridochrom Glucose GOD-PAP, Boehringer, Germany). Serum cholesterol and 
triglycerides were measured in fresh serum samples by enzymatic colorimetric methods 
(CHOD-PAP, GPO-PAP, Boehringer Mannheim GmbH, Germany). Serum high density 
lipoprotein (HDL) cholesterol was measured by the same method after precipitation of 
low-density lipoprotein cholesterol and very low-density lipoprotein cholesterol with 
phosphotungstic acid and magnesium. Glucose and lipids were determined in the routine 
laboratory of Pieksämäki District Hospital. 
Serum hs-CRP was measured with an Immulite analyzer and a DPC high-sensitivity 
CRP assay (DPL, Los Angeles, CA, USA). Serum adiponectin was determined with an 
enzyme immunoassay (Human Adiponectin Elisa Kit, B-Bridge International INC, 
Mountain View, CA, USA). Plasma concentrations of IL-1β and IL-1Ra were determined 
using high-sensitivity calorimetric ELISA Kits HSLB 50 and DRA00 form R&D systems 
(Minneapolis, MN, USA). The sensitivities of the assays were 0.1 pg/ml and 22 pg/ml, 
respectively.  
An oral glucose tolerance test was performed, according to the WHO protocol, using a 
75g glucose load. 
The quantitative insulin sensitivity check index (QUICKI) (94), which was used as a 
marker of insulin sensitivity (Study IV), was calculated as follows: QUICKI = 1/(log FPI + 
log FBG), where  FPI = fasting plasma insulin level expressed as mU/l, and FBG = fasting 
plasma glucose level expressed as mg/dl. 
4.4 DETERMINATION OF THE METABOLIC SYNDROME 
In this study, the MetS was determined according to the NCEP/ATP III criteria: subjects 
with three or more of the following components were classified as having MetS: 1) 
increased waist circumference (≥ 102 cm [≥40 in] for men and ≥88 cm [≥35 in] for women), 
2) elevated fasting total triglycerides (≥1.7 mmol/l [≥150 mg/dl] or treatment for 
dyslipidemia), 3) low fasting serum high-density lipoprotein (HDL) cholesterol (<1.03 
mmol/l [<40 mg/dl] for men and <1.29 mmol/l [<50 mg/dl] for women or treatment for 
dyslipidemia), 4) systolic BP ≥ 130 mmHg or diastolic BP ≥ 85 mmHg or the use of 
antihypertensive medication, and 5) fasting plasma glucose ≥5.6 mmol/l [≥ 100 mg/dl] or 
the use of medication for hyperglycemia.  
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4.5 STATISTICAL ANALYSIS 
The results are expressed as means with standard deviations (SD), or as counts with 
percentages.   
In Study I, a statistical comparison between the genders was performed by t-test or 
bootstrap-type t-test, when appropriate. Statistical significance for the hypotheses of 
linearity was evaluated by using generalized linear models with appropriate distribution 
and link function.  
In Study II, statistical comparisons among the groups were performed by t-test or 
bootstrap-type t-test, when appropriate. Bootstrap-type ANCOVA was used to determine 
BMI and age-adjusted values. The normality of variables was evaluated by Shapiro-Wilk 
test. Confidence intervals (CI) were obtained by bias-corrected bootstrapping (5000 
replications). 
In Study III, the CIs for ORs (Odds Ratio) were obtained by bias-corrected 
bootstrapping (5000 replications). Statistical comparisons between the groups were 
performed by chi-square test, t-test or bootstrap-type t-test, as appropriate. Logistic 
regression models were used to investigate the linear association between the MetS and 
gender-specific tertiles of insulin, hs-CRP, adiponectin and inflammatory cytokines. 
Adjustments were made for age, physical activity, smoking and use of alcohol in model 1, 
and BMI was added for model 2. The normality of variables was evaluated by Shapiro-
Wilk statistics. The Clopper-Pearson method was used to calculate the CI for the 
prevalence rate.  
In Study IV, a statistical comparison between groups was made by t-test, bootstrap-type 
t-test, permutation test, chi-square test or Fisher exact test, when appropriate. Age, change 
in BMI, smoking status and physical activity were added into the model as covariates. The 
95 per cent confidence intervals for the most important outcomes were obtained by bias-
corrected bootstrapping. 
Data processing and statistical analyses were performed using SPSS (v.11.5) and STATA 
(v.11.1) for Windows. 
4.6 ETHICAL CONSIDERATIONS 
In the invitation letters and in the first interview, all the subjects were informed about the 
aims and methods of the study. All the participants gave written consent.  
Questionnaires and the data are confidentially stored in the archives of the Unit of Family 
Practice in Central Finland Central Hospital. 
The study protocol was approved by the Ethics Committee of Kuopio University Hospital 
and the University of Kuopio in 1996. 
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5 Results 
5.1 CHARACTERISTICS OF THE STUDY POPULATION 
The basic demographic, clinical, biochemical and lifestyle characteristics of the study 
subjects are presented in Table 2. The presence of the MetS according to BMI, separately in 
men and women in the study population, is shown in Figure 3. 
 
Table 2. Demographic, clinical, biochemical and lifestyle characteristics of the study population 
 
Variables  Men 
(N=411) 
Mean (SD)  
Women 
(N=512) 
Mean (SD) 
P-value 
Demographic    
  Age, years 46 (6) 46 (6)  
  Body mass index, kg/m² 26.7 (3.8) 26.3 (4.9)    0.15 
  Waist, cm  93.8 (10.6) 83.3 (12.2) < 0.001 
Clinical    
  Blood pressure, mmHg    
    Systolic 137 (17) 131 (17) < 0.001 
    Diastolic  84 (10) 79 (9) < 0.001 
Biochemical    
  HDL cholesterol, mmol/l 1.3 (0.3) 1.5 (0.3) < 0.001 
  Triglycerides, mmol/l 1.7 (1.3) 1.2 (0.6) < 0.001 
  FP-glucose, mmol/l 5.9 (0.6) 5.6 (0.5) < 0.001 
  FP-insulin, mU/l 10.7 (5.9) 9.8 (6.5) < 0.001 
  Hs-CRP, pg/ml 1.3 (1.5) 1.5 (1.7)    0.035 
  IL-1β, pg/ml 0.61 (0.43) 0.61 (0.47)    0.94 
  IL-1Ra, pg/ml 172 (131) 192 (167)    0.16 
  Adiponectin, μg/ml 4.9 (2.7) 7.9 (4.4) < 0.001 
Lifestyle    
  Number of current smokers 
(%) 
136 (33) 112 (22) < 0.001 
HDL= high density lipoprotein, FP= fasting plasma, hs-CRP= high-sensitivity C-reactive 
protein, IL-1β= Interleukin-1 beta, IL-1Ra= Interleukin-1 Receptor antagonist, current 
smoker= a daily smoker 
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Figure 3. The number of male and female study subjects, according to BMI (kg/m²) and the 
presence of the MetS 
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5.2 INTERRELATION BETWEEN ADIPONECTIN AND INFLAMMATORY 
MARKERS 
In correlations, adjusted for age and gender, among measured inflammatory markers 
there were statistically significant negative correlations between adiponectin and IL-1Ra 
(p<0.001) and adiponectin and hs-CRP (P=0.020). A statistically significant positive 
correlation was found between IL-1Ra and hs-CRP (p<0.001) (Table 3). 
Table3. Correlations between adiponectin, interleukin-1 receptor antagonist (IL-1Ra), 
interleukin-1 beta (IL-1β) and high- sensitivity C-reactive protein (hs-CRP) adjusted for age 
and gender 
 
 Adiponectin IL-1Ra IL-1β hs-CRP 
Adiponectin  -0.200 (p<0.001) 0.014 (p=0.72) -0.090 (p=0.020) 
IL-1Ra  -0.200 (p<0.001)  0.016 (p=0.684)  0.343 (p<0.001) 
IL-1β  0.014 (p=0.72)  0.016  (p=0.68)  -0.001 (p=0.99) 
hs-CRP -0.090 (p=0.020)  0.343  (p<0.001) -0.001 (p=0.99)  
 
5.3 GENDER DIFFERENCES IN THE ASSOCIATION OF ADIPONECTIN 
AND LOW-GRADE INFLAMMATION WITH THE RELATIVE CHANGE IN 
BODY MASS INDEX FROM THE AGE OF 20 YEARS TO MIDDLE AGE 
(STUDY I)  
At the age of 20 years, the mean weight was 71 (SD 9) kg in men and 57 (SD 8 ) kg in 
women. The means of BMI were 22.6 (SD 2.5) kg/m² and 21.2 (SD 2.7) kg/m², respectively 
(p<0.001 between genders). The mean increase in weight from the age of 20 years to 
middle-age was 12.8 (SD 11.2) kg in men and 13.9 (SD 11.9) kg in women (p=0.16 between 
genders). There was no significant gender difference in BMI in middle-age. The 
demographical, clinical and biochemical charasteristics of the study subjects at the mean 
age of 46 years are presented in Table 4. 
The associations of adiponectin, IL-1Ra, IL-1β and hs-CRP were examined with the 
quartiles of the relative change in BMI from the age of 20 years to middle-age. There was 
no statistically significant difference in alcohol intake between the quartiles of the relative 
change in BMI in men or in women.  
In men, a statistically significant linear association was observed between quartiles of 
the relative change in BMI and IL-1Ra and hs-CRP levels (p< 0.001 for linearity). This 
significance disappeared after adjusting for BMI in middle-age. (Table 5) 
In women, a statistically significant negative linear association was observed between 
quartiles of the relative change in BMI and levels of adiponectin. There were also 
significant positive linear associations between the change in BMI and levels of IL-1Ra and 
hs-CRP (p <0.001 for linearity). After an adjustment for BMI in middle-age the negative 
association between adiponectin and the relative change in BMI remained significant (p< 
0.001 for linearity), and the positive associations between the change in BMI and levels of 
IL-1Ra and hs-CRP were statistically significant (p<0.05). (Table 5)   
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Associations between socio-economical status and relative change of BMI were also 
examined. The dichotomy between lower and higher socio-economical status was made 
according to total years of education (lower education ≤ 10 years). In men, there was found 
no association between the socio-economical status and the relative change in BMI; the 
proportion of men with higher socio-economical status (n=90) varied from 19% to 26% 
across the tertiles of weight increase (p=0.30 for linearity). In women, there was seen a 
statistically significant difference between the socio-economical status and the relative 
change in BMI. The proportion of women with higher socio-economical status (n=193) 
decreased from 46% to 28% across the tertiles of relative weight increase (p=0.003 for 
linearity). 
Table 4. Demographic, clinical and biochemical characteristics of the Study I population in 
middle age 
Characteristics      Men 
   N=403 
 Mean (SD) 
    Women 
    N=500 
    Mean (SD) 
P-value 
 
 
 
Demographic            
 
   Age, years        46 (6)               46 (6) 0.37 
   Height, cm      177 (6)              163 (6) <0.001 
   Weight, kg       82 (12)                 70 (13) <0.001 
   Body mass index, kg/m²             26.7 (3.7)             26.3 (4.9) 0.14 
  
Clinical 
  
   Blood pressure, mmHg 
         Systolic       137 (17)              131 (17)          <0.001 
         Diastolic        84 (10)                79 (9) <0.001 
 
Biochemical 
 
   Total cholesterol, mmol/l       5.8 (1.0)             5.6 (1.0)          <0.001 
   HDL cholesterol, mmol/l                   1.3 (0.3)             1.5 (0.3)          <0.001 
   Total triglycerides, mmol/l           1.7 (1.3)             1.2 (0.6)          <0.001 
   Fasting plasma glucose, mmol/l          5.9 (0.6)             5.6 (0.5)          <0.001 
    
HDL= high density lipoprotein 
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5.4 GENDER DIFFERENCE AMONG SMOKING, ADIPONECTIN AND      
HS- CRP (STUDY II) 
Among 365 men and 476 women, there were 125 (34%) male and 104 (22%) female 
smokers (p<0.001 between genders). On average, men had smoked for 22 years (95% CI 20-
30 years) and women for 20 years (95% CI 15-25 years, p=0.001 between genders). The 
median number of cigarettes per day was 14 (95% CI 9-20) in men and 10 (95% CI 6-14) in 
women (p< 0.001 between genders).  
Demographic, clinical and biochemical characteristics of the study population divided 
by gender and smoking are presented in Table 6. 
In smoking males, hs-CRP levels were significantly higher compared to non-smoking 
males (1.59±1.71 pg/ml vs. 1.17±1.41 pg/ml, p=0.018). This association remained significant 
after adjusting for age and BMI (p=0.0056). In adiponectin, no significant association 
related to smoking was seen in men. (Figure 4) 
In smoking females, adiponectin levels were significantly lower compared to non-
smoking females (6.94 ± 3.27 μg/ml vs. 8.27 ± 4.72 μg/ml, p=0.0017), with the association 
remaining significant after adjustment for age and BMI (p=0.0061), but no significant 
association between smoking and hs-CRP was seen in women. (Figure 4) 
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Figure 4. Adiponectin and hs-CRP levels and smoking by gender, adjusted for BMI and age
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5.5 GENDER DIFFERENCES RELATED TO THE METABOLIC SYNDROME 
AND LOW-GRADE INFLAMMATION IN SUBJECTS WITH ELEVATED 
BLOOD PRESSURE (STUDY III) 
Subjects using antihypertensive drugs or with systolic BP ≥ 130 mmHg or diastolic BP ≥ 85 
mmHg (278 men, 273 women) were included in this study. There was no statistically 
significant gender differences in the use of antihypertensive medication (14.4% of men, 
14.7 % of women, p=0.930 between genders). The majority of antihypertensive drugs used 
were ACE-inhibitors and β-blockers with no gender differences. Demographic, clinical, 
biochemical and lifestyle factors of the study subjects are shown in Table 7.  
Table 7. Demographic, clinical, biochemical and lifestyle factors of the Study III subjects  
 
Variables  
 
 
Men      
(N=278) 
 
Women 
(N=273) 
 
p-value 
 
Demographic  
   
   Age, years 47 (6) 48 (6) 0.38 
   Age distribution, years 36-57 36-57 NS 
   Body mass index, kg/m² 27.1  (3.8) 27.1 (5.2) 0.98 
   Waist circumference, cm 
 
Clinical 
95 (11) 85 (13) <0.001 
      Blood pressure, mmHg    
        Systolic  146 (15) 144 (14) 0.10 
        Diastolic 88 (9) 85 (8) <0.001 
Medication for hypertension (%) 40 (14) 40 (15) 0.93 
Medication for hyperlipidemia (%) 12 (4.4) 5(2.0) 0.092 
Medication for diabetes (%) 6(2.0) 7(3.0) 0.75 
Biochemical     
     Total cholesterol, mmol/l 5.9 (1.1) 5.7 (1.0) 0.11 
     HDL cholesterol, mmol/l   1.3 (0.3) 1.5 (0.4) <0.001 
     Triglycerides, mmol/l 1.7 (1.4) 1.3 (0.6) <0.001 
     FP-glucose, mmol/l 6.0 (0.7) 5.7 (0.6) <0.001 
Lifestyle     
     Number of current smokers (%) 94 (34) 52 (19) <0.001 
     Number of alcohol users (%) 243 (88) 212 (78) <0.001 
     Number of physically active (%) 87 (31) 78 (27) 0.48 
HDL = high density lipoprotein; FP = fasting plasma (mean, SD in parentheses for continuous 
variables; number of subjects, percentage in parentheses for dichotomous variables)  
   
The MetS, as defined by NCEP criteria, was observed in 35% (95% CI: 30% to 41%) of 
men and 34% (95% CI: 29% to 40%) of women (p=0.84 between genders). There were no 
statistically significant gender differences in the mean BMI, regardless of whether the 
subjects had the MetS (30.0± 3.8 kg/m² in men vs.30.9±5.1 kg/m² in women, p=0.20 between 
37 
 
 
genders) or not (25.6±2.7 kg/m² in men vs. 25.2±4.0 kg/m² in women, p=0.27 between 
genders).  
The difference in adiponectin levels between men and women without the MetS was  
 -3.85μg/ml (95%CI -4.72 to -3.10, p<0.001) and with the MetS -2.53μg/ml (CI 95% -3.44 to -
1.68, p<0,001), respectively. Otherwise there were no gender differences if the MetS was 
not present. Among subjects with the MetS, hs-CRP level was 0.67 pg/ml (95% CI 0.13 to 
1.17, p=0.013) and IL-1Ra level was 77 pg/ml (95% CI 17 to 141, p=0.014) higher in women 
than in men. (Table 8) 
 
Table 8. Insulin, hs-CRP and cytokines, according to the presence of the metabolic syndrome 
 
Variables  MetS not present  MetS present 
   
Men 
(n=181) 
Mean (SD) 
Women 
(n=180) 
Mean (SD) 
p-value 
† 
 Men  
(n=97) 
Mean (SD) 
Women 
(n=93) 
Mean (SD) 
p-value 
† 
FP-insulin, 
mU/l 
9.2 (4.4) 8.4 (2.8) 0.065  15.3 (7.8) 15.0 (12.4) 0.85 
hs-CRP, 
pg/ml 
1.32 (1.58) 1.25 (1.37) 0.65  1.68 (1.70) 2.35 (1.99) 0.013 
Adiponectin, 
μg/ml 
5.02 (2.50) 8.87 (4.84) <0.001  4.11 (2.36) 6.64 (3.72) <0.001 
IL-1Ra, pg/ml 157 (81) 174 (147) 0.17  212 (208) 289 (242) 0.014 
   
† Bootstrap-type t-test, MetS= metabolic syndrome defined by the NCEP criteria, FP= fasting 
plasma, hs-CRP= high sensitive C-reactive protein, IL-1Ra= interleukin 1-receptor antagonist 
 
 
In the association between adiponectin and the MetS, a statistically significant gender 
difference was found; after adjustment for BMI, the OR for the MetS was 0.30 (CI 95% 0.14 
to 0.67) in the highest tertile of adiponectin, compared to the lowest one in females 
(p=0.003), not being significant in males. In males, only level of fP-insulin was associated 
in a statistically significant manner for the risk of the MetS, (p<0.001), and the significance 
was also seen in females (p=0.013). (Table 9)
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5.6 ASSOCIATION OF ADIPONECTIN AND LOW-GRADE INFLAMMATION 
WITH THE COURSE OF THE METABOLIC SYNDROME (STUDY IV) 
In this study, 284 men and 396 women were first divided according to the presence of the 
MetS at the baseline and further divided into four groups, according to the presence of the 
MetS at follow-up. No MetS and Incident MetS groups, as well as Persistent MetS and 
Resolute MetS groups, were compared. 
At baseline, 473 (70%) of the study subjects were not diagnosed with MetS. In the 
follow-up, MetS was present in 102 (22%) of these subjects. MetS was detected at baseline 
in 207 (30%) of the study subjects, but it had resolved in 51 (25%) of these subjects in the 
follow-up. No statistically significant baseline differences in alcohol consumption, 
education, physical activity or marital status were observed in either gender between the 
No MetS and Incident MetS groups or between the Persistent MetS and Resolute MetS 
groups.  
The mean follow-up time was 6.5 (SD0.4) years. Mean weight increased by 1.6 kg 
(range:-19.9 - + 26.2) in men and by 2.47 kg (-18.0 - + 19.8) in women. The change in BMI 
was 0.51 kg/m² (-6.73 - + 7.66) in men and 0.92 kg/m² (-7.03 - + 7.97) in women.The baseline 
demographic, clinical and biochemical characteristics of the study population divided by 
the course of the MetS are shown in Table 10 (men) and Table 11 (women). 
After adjustment for age, change in BMI, smoking and physical activity, the baseline 
adiponectin level was observed to be associated with the course of the MetS in a 
statistically significant manner: in subjects without the MetS at baseline, lower adiponectin 
levels were associated with Incident MetS (p<0.001), while in study subjects with the MetS 
at baseline, lower adiponectin levels were associated with persistence of the MetS 
(p=0.026). (Table 12) 
Furthermore, when the MetS was not present at baseline, increased IL-1Ra and 
decreased IL-1β levels were associated with the Incident MetS (p=0.004 and p=0.039, 
respectively). In subjects with the MetS at baseline, higher IL-1Ra and hs-CRP 
concentrations were associated with persistence of the MetS (p=0.044 and p=0.036, 
respectively). (Table 12 and Figure 5) 
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No MetS: MetS not present at the first or the second measurement 
Incident MetS: MetS not present at the first measurement but present at the second one 
Persistent MetS: MetS present at the first and the second measurement   
Resolute MetS: MetS present at the first measurement but not at the second one 
 
Figure 5. Associations between the course of metabolic syndrome and levels of adiponectin, hs-
CRP, IL-1Ra and IL-1β in males and females, adjusted for age, change in BMI, smoking status 
and physical activity (Mean ±95% CI)   
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6 Discussion  
6.1 STUDY POPULATION, DESIGN AND METHODS 
The study population consisted of five entire age groups (born in 1942, 1947, 1952, 1957 and 
1962, n=1294) from one town. Three separate invitations were sent to subjects, according to 
the civil register, without any excluding criteria. The number of participants is 
representative (n=923, 71.3%, 411 men, 512 women) with no statistical gender differences in 
the number of subjects in any age group. Among the population of the second check-up, 
there were 681 same subjects as in the first check up (73.8%). Because this was a population-
based study with invitations sent by mail, it is not possible to know the reasons why all of 
the invited persons did not participate or why some of them decided to participate only in 
one of the two check-ups. In previous research, among non-respondents there are those 
who have, in general, negative attitude towards medical care or who feel this kind of 
survey as an unpleasant reminder of own unhealthy lifestyle (308). The reason for non-
respondence was not analyzed in this study but it, as well as the fact, that the study 
population is genetically homogenous, may limit the generalization of the results. 
Two nurses, who interviewed and examined all the subjects, were specially trained for 
this task. At every stage, study subjects with elevated hs-CRP level (hs-CRP ≥ 10 pg/ml, 
except in Study IV hs-CRP≥ 30 pg/ml), were excluded; thus, latent infections or 
inflammatory conditions like tissue damage were unlikely to bias results as far as 
inflammatory markers are concerned. With these cut-off points of hs-CRP, bacterial and 
most viral infections are eliminated, according to previous research (309,310). The 
determinations of adiponectin and cytokines were done in the scientific laboratory of the 
University of Kuopio at the same time in 2003 in order to minimize inter-assay variations. 
The samples were immediately frozen to -20°C and stored in -70°C. Previous research 
shows evidence that adiponectin in samples stored in -70°C is reproducible, even after two 
frozen-thaw periods, with more years of storage than the samples in this research (311,312). 
Also, as regards inflammatory markers, storage in-70°C has been proven in previous 
research not to impair the reliability of the results (313). 
The strengths of Study I are the population-based setting and moderately large number 
of subjects (403 men and 500 women). The fact that weight and height at the age of 20 years 
were asked instead of obtained from registers is a weakness. There is, however, support for 
that method in previous research, with the result that self-reported measurements can be 
used when estimating health risks, and that long-term memory of past weight is relatively 
good (314,315). Additionally, the retrospective setting with measurements of adiponectin 
and inflammatory markers only in middle age must be considered a limitation, as it only 
shows association with the change in BMI and not any prediction between these markers 
and BMI change. This setting does not, however, weaken the main findings concerning 
gender differences in this topic. 
The percentage of smokers in Study II was 34% of males and 22% of females. This is in 
line with the statistics of the Finnish National Institute for Health and Welfare regarding 
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the number of smokers in Finland in 1996-1998 (316). In this study, diabetic subjects were 
also excluded; thus the associations of adiponectin and hs-CRP with smoking were 
examined in an apparently healthy population with a broad sampling of five age groups. 
However, the cross-sectional setting and the fact that other forms of tobacco were not 
examined must be considered as limitations. 
In Study III, the number of subjects (both men and women) receiving medication for 
hypertension (n=40 vs. 40), diabetes (n=6 vs. 7) or hyperlipidemia (n=12 vs. 5) was relatively 
small and there were no gender differences in either medication group; thus, medications 
are not likely to bias the results. The MetS was observed in 35% of men and 34% of women, 
which is in line with earlier research (58, 59). However, the total number of subjects with 
the MetS was relatively small in this study (97 men and 93 women). 
In Study IV, concerning the associations of inflammatory markers with the course of the 
MetS, the longitudinal setting is an advantage. However, the small number of subjects in 
the groups divided by the MetS status is a limitation. Additionally, there were only two 
health check-ups and points of laboratory measurements, which may bias the results; the 
status of the MetS may have varied according to the study period. 
In addition to the limitations mentioned above, it is necessary to state that this study did 
not include accurate measurements of fat distribution; waist circumference was used 
instead. In epidemiological studies, this and other simple fat distribution measurements 
have proven to be useful and reliable, but naturally they cannot be as exact as 
measurements made using radiological methods (132). Another limitation is the fact that in 
this study, like in the majority of earlier population-based studies focused on inflammatory 
markers, only total adiponectin was determined instead of high-molecular-weight 
adiponectin or the ratio of high-molecular-weight and middle-molecular weight 
adiponectin, which seems to be especially related to insulin resistance (317).  
6.2 ADIPONECTIN, IL-1RA AND HS-CRP ASSOCIATED WITH RELATIVE 
WEIGHT GAIN IN WOMEN 
This study reveals that there is a gender difference in the association between the relative 
change in BMI from the age of twenty years to middle age and low-grade inflammation 
measured by adiponectin, IL-1Ra and hs-CRP, after adjusting for BMI in middle age. 
Adiponectin is associated linearly in an inverse fashion and IL-1Ra and hs-CRP are 
associated linearly with the change in BMI in women; there was no significant association 
in men. 
Adiponectin levels are known to decline with weight gain, even before weight gain 
reaches the level of obesity (8). Furthermore, adiponectin levels have been shown to 
increase in subjects who manage to reduce their weight (318). On the other hand, the level 
of adiponectin at baseline was not found to be associated with future weight gain in Pima 
Indians. In another study of elderly subjects, adiponectin was not found to predict changes 
in weight (319,320). According to findings mentioned above, it might be presumed that 
decreased adiponectin may not perform an etiological role in obesity but more likely is a 
consequence of weight gain. There is evidence that adiponectin may act as a promoter in 
the network of inflammatory and anti-inflammatory cytokines. With decreased adiponectin 
synthesis, it is likely that the control mechanisms of the production of many inflammatory 
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and anti-inflammatory cytokines are inhibited (14). Not only is adiponectin capable of 
increasing the production of anti-inflammatory IL-1Ra, but it can also suppress the 
synthesis of several inflammatory cytokines and down-regulate CRP synthesis and 
secretion (14,24).  
Physiologically, there is a gender-specific division in fat distribution: men have more 
visceral fat and women have more subcutaneous fat (321). Aging, in particular, increases 
the visceral fat component of weight gain in women (322,323). It has previously been 
suggested that the mass of intra-abdominal fat determines adiponectin levels (324). On the 
other hand, there is no evidence of gender difference in adiponectin levels when the 
amount of intra-abdominal and hepatic fat is similar between genders (325). In animal 
models, it has been shown that removal of visceral fat restores insulin action, elevates 
adiponectin levels and reduces inflammatory cytokine levels (326, 327). In the present 
study, adiponectin levels adjusted for BMI in middle age decreased significantly in a linear 
fashion with the relative change of BMI in women; this was not the case in men. The 
amount or distribution of fat was not examined in the present study. However, based on 
the research mentioned above, it can be presumed that with weight gain, fat accumulates 
primarily in the intra-abdominal division and is relatively more abundant in elderly 
women than in men (322, 323). This presumption might partly explain the finding of this 
study concerning a gender-specific difference in adiponectin levels. 
White adipose tissue is the main producer of IL-1Ra in obesity and inflammation, and it 
is speculated that this cytokine contributes to future weight gain (20). There is evidence that 
IL-1Ra may be differentially secreted and may also function differently in men and women 
(37). In another study carried out in subjects with Cushing syndrome, elevated IL-1Ra 
levels were particularly associated with centrally-located fat (328). In women, weight gain 
and particularly increased accumulation of central body fat begin before menopause (323). 
In the present study, after adjusting for BMI in middle age, IL-1Ra was associated with 
relative weight change only among women. The present results concerning this gender 
difference in IL-1Ra levels, while not capable of revealing any causality between IL-1Ra and 
increased BMI could stem from the earlier results mentioned above. The present findings 
concerning the decrease in adiponectin levels and the increase in IL-1Ra levels in women 
are also in line with previous results (37, 322, 323) concerning the relationship between 
adiponectin and IL-1Ra, and they may give further support to the theory that adiponectin 
acts as a promoter in the network of inflammation. 
In this study, no association between IL-1β and relative change in BMI was found. This 
might be due to the previously known fact that IL-1β levels are often not elevated in 
circulation (16). Furthermore, increased IL-1β levels are speculated to be associated with 
pancreatic β-cell damage and the diabetic state (329). In the present study population, there 
were only a few diabetic subjects. 
It has been previously confirmed that weight gain and obesity influence the 
development of the MetS and T2D through inflammatory mechanisms (14). In a study of 
the associations between components of the MetS and CRP, the strongest association was 
found between CRP and BMI; furthermore, CRP levels increased with an increasing 
number of components of the MetS (213). In the present study, hs-CRP was significantly 
and positively associated with the relative change in BMI in both genders. After adjusting 
for BMI in middle age, this association disappeared in men and remained significant in 
47 
 
 
women. This result is in line with a study on the effect of weight gain on pulmonary 
diseases and systemic inflammation measured by hs-CRP, in which weight gain had a 
stronger effect on inflammation in women than in men (330). That kind of gender difference 
was also presented in a follow-up study of 11 years, concerning change of body 
composition and inflammatory markers (331). 
It is well known that lower socio-economical status is firmly linked to greater weight 
gain in Western countries (332,333). In the present study, duration of education was used as 
a marker of socio-economical status. A gender difference was also found in this respect, 
with a greater relative change in BMI in women with lower education level. The MetS has 
been observed to have a different association with the risk of CVD between genders; it is a 
stronger predictor of cardiovascular diseases in women than in men and has a greater effect 
on left ventricular function and hypertrophy in women, compared to men (32,33). Based on 
these results, we should pay special attention to the health counseling of young women 
with lower education levels (which may reflect lower socio-economical status) in order to 
prevent cardiovascular consequences.  
The findings of this study concerning the associations between relative weight change 
and decreased adiponectin levels and increased IL-1Ra and hs-CRP levels in women but 
not in men support the theory that the underlying mechanisms of obesity and obesity-
related diseases differ between genders. It can be concluded that an increase in fat mass 
may be more harmful to women than men with respect to adiponectin and inflammatory 
markers. However, further research with a prospective study setting is needed to confirm 
these results. 
6.3 SMOKING, HS-CRP AND ADIPONECTIN  
The novel finding in this study was the gender difference in levels of adiponectin and hs-
CRP related to smoking in a non-diabetic population; in males, hs-CRP, but not 
adiponectin, was associated with smoking; in females, there was an association between 
adiponectin and smoking, but not between hs-CRP and smoking. 
Earlier research reveals a significant inverse association between adiponectin and 
smoking in both genders (181). In another study with smoking males, a significant decrease 
of adiponectin levels was seen in currently smoking men, compared to men who never 
smoked (277). The association was still present when diabetic subjects and subjects with 
regular drug use were excluded, but what is noticeable is that these men were likely ten 
years older in terms of mean age compared to smoking men in the present study, which 
may affect to the results. Similar with the results of the present study, Sonmez et al. did not 
find in their work any alteration in adiponectin levels in the population of healthy young 
male smokers with regular exercise habits, compared to non-smokers (334). 
The associations between smoking and adiponectin levels in women have been hardly 
studied. Smoking has been speculated to directly affect fat distribution via an increase in 
visceral fat deposits (335). This theory is supported by the results where especially in 
premenopausal women smoking was associated with increased visceral fat and reduced 
femoral fat, compared to non-smoking women (336). 
The present study found an association between elevated hs-CRP in male smokers 
compared to non-smoking males; this is in line with earlier results (337, 338). Additionally 
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there is evidence in the COPD study that higher CRP levels are associated with a higher 
decline in FEV1 in men, compared to women (339). Unlike other previous studies which 
also included diabetic subjects, hs-CRP levels were not associated with smoking in the non-
diabetic female population of this study (340). Contrary to synthesis of adiponectin, which 
appears mainly in adipocytes of subcutaneous adipose tissue, inflammatory cytokines are 
secreted mostly from non-fat cells in adipose tissue (341). Smoking might have an influence 
on compounds of visceral adipose tissue outside the adipocytes, causing the release of 
interleukin-6, which results in increased hs-CRP production in hepatic cells (342). Due to 
the larger visceral fat deposits present in men, there may be greater production of hs-CRP 
in men compared to women, as seen in the present study. 
In conclusion, there was a gender difference in the associations between smoking and 
adiponectin and hs-CRP levels found in the present study. This finding may suggest that 
the detrimental effects of smoking may be partly mediated by different paths, according to 
gender. Further research is warranted to determine whether fat distribution can explain 
gender-specific associations of adiponectin and hs-CRP with smoking. Both adiponectin 
and hs-CRP are indicators of future risk of the MetS and CVD. The results of this study thus 
further support harmful effects of smoking. 
6.4 GENDER DIFFERENCES REGARDING LOW-GRADE INFLAMMATION IN 
SUBJECTS WITH ELEVATED BLOOD PRESSURE AND THE METABOLIC 
SYNDROME 
In Study III, it was shown that in hypertensive subjects with the MetS, as defined by NCEP 
criteria, women had higher levels of IL-1Ra and hs-CRP compared to men. Furthermore, 
absolute differences between genders in these inflammatory markers were greater in 
subjects with the MetS, compared to subjects without the MetS. Additionally, women had a 
threefold risk for the MetS in the lowest adiponectin tertile, compared to the highest one, 
even after removal of potential confounding factors, while no statistical OR for the MetS 
was found in men.  Though adiponectin levels were higher in women despite their MetS 
status, the absolute difference between genders was about 1.3 μg/ml lower in the subjects 
with the MetS compared to subjects without the MetS. This suggests that adiponectin is a 
more important factor in the MetS in women, compared to the MetS in men, at least in 
hypertensive subjects. In women, fat is known to accumulate in the subcutaneous depots, 
especially in the gluteal-femoral region (343). With the MetS, accumulation of visceral fat 
also increases in women (344). This change in fat deposits may lead to a decrease in 
adiponectin production. While an adiponectin decrease has been assumed to lead to 
dysregulation of those control mechanisms that inhibit the production of pro-inflammatory 
cytokines (14), it can be speculated that a greater decrease in adiponectin levels in women 
(compared to men) reflects more severe low-grade inflammation in women than in men 
with the MetS. 
IL-1β is shown to be increased in visceral adipose tissue in obese subjects and also in 
patients with essential hypertension, but IL-1β levels are seldom elevated in plasma, while 
anti-inflammatory IL-1Ra is constantly present in the circulation and antagonizes IL-1β 
binding to the cell receptors (16, 20). Increased IL-1β levels are often associated with 
elevated levels of hs-CRP, which is synthesized in the liver in response to IL-1β (345). 
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Previously there has been evidence that elevated IL-1Ra levels might be associated with 
centrally located fat (328).  
A statistically significant gender difference in the ratio of hs-CRP levels between subjects 
with and without the MetS was detected in the present study, indicating that the absolute 
increase in hs-CRP was greater in women, compared to men, among subjects with the 
MetS. Furthermore, there was a larger relative increase in IL-1Ra levels in women with the 
MetS than in men with the MetS. These findings might also be explained by altered fat 
distribution, with more centrally located fat as mentioned earlier in this text. These findings 
are also in line with previous results that disturbances in the regulation of inflammatory 
cytokines are associated with decreased adiponectin levels (14).Regarding gender-specific 
associations of CRP with insulin resistant states, the earlier results are controversial. High 
levels of hs-CRP proved a better predictor of type 2 diabetes in women than in men in the 
MONICA/KORA study (34). Increased CRP levels were also more pronouncedly related to 
the components of the MetS in women than in men in a Japanese study with an apparently 
healthy population (346). On the other hand, in the Hoorn study a significant association of 
hs-CRP with incident diabetes mellitus was observed in men, but not in women (347). In 
Japanese subjects, this association was observed in both sexes (348); in the Mexico City 
Diabetes Study it was only observed in women (294).  
Elevated plasma insulin is widely used as a marker of insulin resistance (349), at least in 
large population studies where more accurate methods such as the insulin clamp technique 
cannot be used. Excessive mobilization of free fatty acids takes place in the visceral adipose 
tissue through a higher rate of lipolysis in visceral fat, compared to subcutaneous fat. High 
levels of free fatty acids inhibit insulin-mediated glucose uptake in skeletal muscle, leading 
to insulin resistance (87,350). The increase in circulating free fatty acids also increases 
insulin secretion, leading to hyperinsulinemia. In the present study, insulin resistance 
measured by fasting insulin was similarly associated with the MetS in both genders, 
showing a risk of the MetS to be 22-fold in men and 18-fold in women in the highest tertile 
of fasting insulin, compared to the lowest tertile. This risk remained statistically significant 
even after adjustment for BMI, emphasizing the central role of insulin resistance in the 
MetS. 
In conclusion, in hypertensive subjects gender differences were found in relation to 
adiponectin, hs-CRP and IL-1Ra and the MetS. Low-grade inflammatory markers were 
more pronouncedly present and the changes in their levels were more disadvantageous in 
women than in men. Further research is needed to estimate the significance of these 
findings and possible connections to the previously shown results that the MetS may be a 
stronger predictor of cardiovascular diseases among women, compared to men (32). 
6.5 ADIPONECTIN AND INFLAMMATORY MARKERS IN THE COURSE OF 
THE METABOLIC SYNDROME 
The novel finding in this longitudinal follow-up study of 6.5 years was the baseline 
adiponectin, and also IL-1Ra and IL-1β levels, to predict the Incident MetS. Additionally, 
this data suggested that higher adiponectin levels and lower hs-CRP and IL-1Ra levels may 
predict the resolution of the MetS. 
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The MetS is strongly associated with obesity. The change in BMI has been shown to 
predict the development of the MetS in several studies (351 - 354), which has led to 
speculations that the change in BMI is the central factor in the course of the MetS. In the 
present study, adiponectin was found to predict the course of the MetS independently of 
the change of the BMI. Adiponectin levels are associated inversely with obesity, the MetS 
and inflammatory markers (14,166). Low adiponectin levels have also been considered as 
an independent risk factor for the MetS (355). On the other hand, there is evidence in a 
study carried out with the Pima Indian population that high adiponectin levels provide 
protection against T2D (173). The findings in the present study concerning the association 
of higher baseline adiponectin levels with a more favorable course of the MetS are in line 
with these earlier findings and provide further support to the theory that adiponectin may 
partly modulate the process underlying the development of the MetS. 
IL-1Ra is known to possess anti-inflammatory properties, but it also reflects the 
inflammatory response (16). Both IL-1Ra and IL-1β levels have been found to increase in 
the MetS, and it has been suggested that they may be better markers of the MetS than TNF-
α or interleukin-6 (161). Increased IL-1Ra levels are known to precede T2D (194). After the 
present results were collected, another Finnish study has come out in which it was shown 
that IL-1Ra predicts the MetS to proceed to incident diabetes independently of CRP or 
traditional risk factors (356); however, in a literature review, no research was found 
concerning IL-1Ra as a predictor of the MetS. In a study of increased IL-1Ra preceding T2D, 
the investigators speculated that IL-1Ra may protect against the pro-inflammatory effects of 
IL-1β, or, on the other hand, have independent metabolic effects leading to insulin 
resistance. It was not possible to find further information concerning that speculation, but 
nevertheless these earlier findings support the results of the present study in terms of the 
association between elevated IL-1Ra levels and both Incident and Persistent MetS, which 
often precede type 2 diabetes. The results of this study are also in line with recent findings 
in which subjects with an intense pro-inflammatory state measured also by IL- 1Ra, 
regardless of BMI, have a higher probability of developing the MetS (195). 
In this study, it was found out that lower IL-1β levels are associated with Incident MetS 
in males and in the combined study population, which is a somewhat surprising result 
when previous data is taken into account. Compared to other cytokines, it seems that the 
synthesis and secretion of IL-1β is more strictly regulated (357). Furthermore, IL-1β has also 
been speculated to be associated with pancreatic β-cell damage and a diabetic state (329). A 
low IL-1Ra/IL-1β ratio is associated with newly diagnosed insulin-dependent diabetes 
mellitus and with certain inflammatory states like osteoarthritis (197,198). The present 
population included only a few diabetic subjects, which may also have affected the IL-1β 
levels measured in this study. 
CRP synthesis is decreased by adiponectin and it is stimulated by IL-1β and IL-6 
(24,358,359). Those subjects in the present population who had the MetS at both check-ups 
had higher absolute hs-CRP levels, which might indicate longer and more advanced low-
grade inflammation, compared to the other three groups. Longer exposure to low-grade 
inflammation in the Persistent MetS group might partly explain the finding that there was 
no significant association between hs-CRP and Incident MetS, but that such an association 
was observed when Persistent and Resolute groups were compared. In the present study, 
however, the exact length of the different MetS statuses was not examined, so this can only 
51 
 
 
be speculated about. This speculation, however, is supported by earlier research, which 
provides evidence of hs-CRP acting as a marker of vascular inflammation instead of 
directly promoting atherosclerosis (359). 
In conclusion, decreased adiponectin level and increased levels of hs-CRP and IL-1Ra 
were found in this study to associate with the persistence of the MetS. These findings 
provide further support to the role of inflammation in the MetS. Further research is 
warranted to determine whether adiponectin or other inflammatory markers could be used 
in clinical practice when trying to predict the course of the MetS and risk of CVD and T2D. 
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7 Summary and Conclusions  
This study was done to evaluate adiponectin and low-grade inflammatory markers with 
factors that generally precede the MetS. Additionally it was aimed at investigating levels of 
low-grade inflammatory markers with respect to the course of the MetS. Due to evidence 
presented in earlier research, a gender-specific view was adopted in this study. 
The main results were: 
1. Decreased adiponectin and increased hs-CRP and IL-1Ra levels were associated with 
a relative increase in BMI from twenty years to middle age in women, but not in 
men. The proportion of women with lower socioeconomic status and education 
increased with relative weight gain; in men there was no such association. 
2. In an apparently healthy non-diabetic population, increased hs-CRP levels in men 
and decreased adiponectin levels in women were associated with smoking.  
3. Women with elevated blood pressure and the MetS had significantly higher levels of 
IL-1Ra and hs-CRP, compared to men. In insulin levels no gender differences were 
seen. In hypertensive women with the lowest tertile of adiponectin, the risk for the 
MetS was threefold; no association was seen in men.   
4. Decreased baseline adiponectin and increased IL-1Ra levels were associated with the 
appearance and the persistence of the MetS. Increased baseline hs-CRP was 
associated with the persistence of the MetS. No gender differences were seen in the 
association between adiponectin, low-grade inflammation and the course of the 
MetS in this study population. 
 
In conclusion, decreased adiponectin levels in women were associated with grater relative 
weight gain, smoking and, especially, in the hypertensive women with an increased risk for 
the MetS. Grater relative weight gain was associated with increased inflammatory markers 
in women, but this association was not seen in men.  Women with elevated blood pressure 
and the MetS had increased low-grade inflammatory markers compared to men. 
Hypoadiponectinemia and increased low-grade inflammation suggest an unfavorable 
course of the MetS in both genders.  
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8 Future directions 
This study adds to the growing evidence that low-grade inflammation is associated with 
metabolic risk factors like weight gain, smoking and hypertension. Gender differences 
found in the results suggest that low-grade inflammation may be mediated differently 
between sexes. The inflammatory markers may be beneficial in terms of the detection of the 
MetS and its progression to CVD and/or T2D. 
From the present data it is not possible to draw any causal relationship between low-
grade inflammation and the progression of the MetS. In the future, it will be important to 
also characterize other inflammatory mediators. A continuous chain from epidemiologic 
observation to biochemical background and treatment intervention is warranted. Some 
preliminary treatment interventions have already been done that suggest the role of 
inflammation in the progression of T2D. Promising results have been published on the 
ability of anakindra, specific IL-1Ra antibodies, to slow down the clinical progression of 
T2D   (360). 
It is imperative for clinical medicine to find a simple and affordable test to reliably detect 
the MetS and its risk to progress to diabetes and/or premature cardiovascular morbidity, in 
order to be able to focus on better prevention and treatment for high- risk individuals. 
   
54 
 
 
9 References 
1) Executive summary of the third report of the National Cholesterol Education 
Program (NCEP) expert panel on detection, evaluation, and treatment of high blood 
cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285:2486-97.  
2) Grundy SM, Hansen B, Smith SC Jr, Cleeman JI and Kahn RA; American Heart 
Association; National Heart, Lung, and Blood Institute; American Diabetes 
Association Clinical management of metabolic syndrome: report of the American 
Heart Association/National Heart, Lung, and Blood institute/American Diabetes 
Association conference on scientific issues related to management. Circulation 2004; 
109:551–6. 
3) International Diabetes Federation, The IDF consensus worldwide definition of the 
metabolic syndrome.2006.www.idf.org/metabolic-syndrome 
4) Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al; 
American Heart Association; National Heart, Lung and Blood Institute. Diagnosis 
and management of the metabolic syndrome: an American Heart 
Association/National Heart, Lung and Blood Institute Scientific Statement. 
Circulation 2005; 112:2735-52. 
5) Alexander CM, Landsman PB, Teutsch SM, Haffner SM; Third National Health and 
Nutrition Examination Survey (NHANES III); National Cholesterol Education 
Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of 
coronary heart disease among NHANES III participants age 50 years and older. 
Diabetes 2003; 52:1210-4. 
6) Eckel R. Mechanisms of the components of the metabolic syndrome that predispose 
to diabetes and atherosclerotic CVD. Plenary lecture. Proc Nutr Society 2007; 66:82-
95. 
7) Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome 
and cardiovascular disease. Nutrition, Metabolism and Cardiovascular Diseases 
2007; 17:319-26. 
8) Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 
2004; 89:2548-56. 
9) Nishida M, Funahashi T, Shimomura I. Pathophysiological significance of 
adiponectin. Med Mol Morphol 2007; 40:55-67. 
10) Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased 
plasma adiponectin concentration in patients with essential hypertension. Am J 
Hypertens 2003; 16:72-5. 
55 
 
 
11) van der Vleuten GM, van Tits LJ, den Heijer M, Lemmers H, Stalenhoef AF, de Graaf 
J. Decreased adiponectin levels in familial combined hyperlipidemia patients 
contribute to the atherogenic lipid profile. J Lipid Res 2005; 46:2398–404. 
12) Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. 
Adiponectin as a biomarker of the metabolic syndrome. Circ J 2004; 68:975-81. 
13) Matsushita K, Tamakoshi K, Yatsuya H, Wada K, Otsuka R, Takefuji S, et al. Further 
inflammatory information on metabolic syndrome by adiponectin evaluation. Int J 
Cardiol 2008; 124:339-44. 
14) Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, 
inflammation and immunity. Nat Rev Immunol 2006; 6:772-83. 
15) Dalekos GN, Elisaf M, Bairakatri E, Tsolas O, Siamopoulos KC. Increased serum 
levels of interleukin-1 beta in the systemic circulation of patients with essential 
hypertension: additional risk factor for atherogenesis in hypertensive patients? J Lab 
Clin Med 1997; 129:300-8. 
16) Peeters ACTM, Netea MG, Janssen MC, Kullberg BJ, Van der Meer JW, Thien T. Pro-
inflammatory cytokines in patients with essential hypertension. Eur J Clin Invest 
2001; 31:31-6. 
17) Jager J, Grémeaux T, Cormont M, Le Marchand-Brustel Y, Tanti J-F. Interleukin-
1beta-induced insulin resistance in adipocytes through down-regulation of insulin 
receptor substrate-1 expression. Endocrinology 2007; 148:241-51. 
18) Abbatecola AM, Ferrucci L, Grella R, Bandinelli S, Bonafè M, Barbieri M, et al. 
Diverse effect of inflammatory markers on insulin resistance and insulin-resistance 
syndrome in the elderly. J Am Geriatr Soc 2004; 52:399–404. 
19) Ruotsalainen E, Salmenniemi U, Vauhkonen I, Pihlajamäki J, Punnonen K, 
Kainulainen S, et al. Changes in inflammatory cytokines are related to impaired 
glucose tolerance in offspring of type 2 diabetic subjects. Diabetes Care 2006; 
29:2714-20. 
20) Juge-Aubry CE, Somm E, Giusti V, Pernin A, Chicheportiche R, Verdumo C, et al. 
Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in 
obesity and inflammation. Diabetes 2003; 52:1104-10. 
21) Bautista LE, Atwood JE, O´Malley PG, Taylor AJ. Association between C-reactive 
protein and hypertension in healthy middle-aged men and women. Coron Artery 
Dis 2004; 15:331-6. 
22) Yeh ET. High-sensitivity C-reactive protein as a risk assessment tool for 
cardiovascular disease.  Clin Cardiol 2005; 28:408-12. 
23) Yap SH, Moshage HJ, Hazenberg BP, Roelofs HM, Bijzet J, Limburg PC, et al. Tumor 
necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of 
C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human 
hepatocytes. Biochim Biophys Acta 1991; 1091:405-8. 
56 
 
 
24) Devaraj S, Torok N, Dasu MR, Samols D, Jialal I. Adiponectin decreases C-reactive 
protein synthesis and secretion from endothelial cells: evidence for an adipose tissue 
–vascular loop. Arterioscler Thromb Vasc Biol 2008; 28:1368-74.  
25) Greenfield JR, Samaras K, Jenkins AB, Kelly PJ, Spector TD, Gallimore JR, et al. 
Obesity is an important determinant of baseline serum C-reactive protein 
concentration in monozygotic twins, independent of genetic influences. Circulation 
2004; 109:3022-8. 
26) Chiolero A, Faeh D, Paccaud F, Cornuz J. Consequences of smoking for body weight, 
body fat distribution, and insulin resistance. Am J Clin Nutr 2008; 87:801-9. 
27) Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic effects 
of smoking. Chest 2007; 131:1557-66. 
28) Yamashita S, Nakamura T, Shimomura I, Nishida M, Yoshida S, Kotani K, et al. Insulin 
resistance and body fat distribution. Diabetes Care 1996; 19:287-91. 
29) Guldiken S, Tuncbilek N, Okten OO, Arikan E, Tuqrul A. Visceral fat thickness 
determined using ultrasonography is associated with anthropometric and clinical 
parameters of metabolic syndrome. Int J Clin Pract 2006; 60:1576-81. 
30) Sandeep S, Gokulakrishnan K, Velmurugan K, Deepa M, Mohan V. Visceral & 
subcutaneous abdominal fat in relation to insulin resistance & metabolic syndrome in 
non-diabetic south Indians. Indian J Med Res 2010; 131:629-35.  
31) Krotkiewski M, Björntorp P, Sjöström L, Smith U. Impact of obesity on metabolism in 
men and women. Importance of regional adipose tissue distribution. J Clin Invest 1983; 
72:1150-62. 
32) Pischon T, Hu FB, Rexrode KM, Girman CJ, Manson JE., Rimm EB. Inflammation, the 
metabolic syndrome, and risk of coronary heart disease in women and men. 
Atherosclerosis 2008; 17:392-99. 
33) Schillaci G, Pirro M, Pucci G, Mannarino MR, Gemelli F, Siepi D, et al. Different impact of 
the metabolic syndrome on left ventricular structure and function in hypertensive men 
and women. Hypertension 2006; 47:881-6. 
34) Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, Koenig W, et al. Sex 
differences in the prediction of type 2 diabetes by inflammatory markers: results from the 
MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 2007; 30:854-60. 
35) Juutilainen A, Kortelainen S, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Gender 
difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes 
Care 2004; 27:2898-904. 
36) Rivellese AA, Riccardi G, Vaccaro O. Cardiovascular risk in women with diabetes. 
Nutr Metab Cardiovasc Dis 2010; 20:474-80. 
37) Lynch EA, Dinarello CA, Cannon JG. Gender differences in IL-1 alpha, IL-1 beta and IL-1 
receptor antagonist secretion from mononuclear cells and urinary excretion. J Immunol 
1994; 153:300-6. 
57 
 
 
38) Kylin E. Studien ueber das Hypertonie-Hyperglykämie-Hyperurikämiesyndrom. 
Zentralblatt fuer Innere Medizin 1923; 44:105-127. 
39) Vague J. La differenciation sexuelle, facteur determinant des formes de l'obesite. 
Presse Med 1947; 30:339-40. 
40) Kannel WB, Gordon T, Castelli WP. Obesity, lipids and glucose intolerance. The 
Framingham Study. Am J Clin Nutr 1979; 32:1238-45. 
41) Albrink MJ, Krauss RM, Lindgrem FT, von der Groeben J, Pan S, Wood PD. 
Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in 
a normal population. Lipids 1980; 15:668-76. 
42) Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. 
Diabetes 1988; 37:1595-607. 
43) DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible 
for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular 
disease. Diabetes Care 1991; 14:173-94. 
44) Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, 
hypertriglyceridemia, and hypertension. Arch Intern Med 1989; 149:1514-20. 
45) Alberti K, Zimmet P. Definition, diagnosis and classification of diabetes mellitus and 
its complications. Part 1: diagnosis and classification of diabetes mellitus provisional 
report of a WHO consultation. Diabetic Med 1998; 15:539-53. 
46) Jager A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. 
Microalbuminuria is strongly associated with NIMDD and hypertension, but not 
with the insulin resistance syndrome: the Hoorn Study. Diabetologia 1998; 41:694-
700. 
47) Foyle WJ, Carstensen E, Fernández MC, Yudkin JS. Longitudinal study of 
associations of microalbuminuria with the insulin resistance syndrome and sodium-
lithium countertransport in nondiabetic subjects. Arterioscler Thromb Vasc Biol 
1995; 15:1330-37. 
48) Balkau B, Charles MA. Comment on the provisional report from the WHO 
consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet 
Med 1999; 16:442-3. 
49) Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, et al. 
American College of Endocrinology position statement on the insulin resistance 
syndrome. Endocr Pract  2003; 9:237-52. 
50) Nakagami T, Qiao Q, Carstensen B, Nhr-Hansen C, Hu G, Tuomilehto J, Balkau B, 
Borch-Johnsen K; DECODE-DECODA Study Group. Age, body mass index and 
Type 2 diabetes-associations modified by ethnicity. Diabetologia 2003; 46:1063-70. 
51) Rush E, Plank L, Chandu V, Laulu M, Simmons D, Swinburn B, et al. Body size, 
body composition, and fat distribution: a comparison of young New Zealand men of 
European, Pacific Island, and Asian Indian ethnicities. N Z Med J 2004; 117:U1203. 
58 
 
 
52) Wang J, Thornton JC, Russell M, Burastero S, Heymsfield S, Pierson RN Jr. Asians 
have lower body mass index (BMI) but higher percent body fat than do whites: 
comparisons of anthropometric measurements. Am J Clin Nutr 1994; 60:23–8. 
53) Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol 
Education Program Adult Treatment Panel definition of the metabolic syndrome to 
Asians? Diabetes Care 2004; 27:1182-86. 
54) Alberti KG, Zimmet P, Shaw J; IDF Epidemiology Task Force Consensus Group. The 
metabolic syndrome- a new worldwide definition. Lancet 2005; 366:1059-62. 
55) Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, et al; Expert 
Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up 
report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26:3160-7. 
56) Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. 
International Diabetes Federation Task Force on Epidemiology and Prevention; 
National Heart, Lung, and Blood Institute; American Heart Association; World 
Heart Federation; International Atherosclerosis Society; International Association for 
the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim 
statement of the International Diabetes Federation Task Force on Epidemiology and 
Prevention; National Heart, Lung, and Blood Institute; American Heart Association; 
World Heart Federation; International Atherosclerosis Society; and International 
Association for the Study of Obesity. Circulation 2009; 120:1640–5. 
57) Ford ES, Giles WH. A comparison of the prevalence of the metabolic syndrome 
using two proposed definitions. Diabetes Care 2003; 26:575-81. 
58) Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome 
among U.S. adults. Diabetes Care 2004; 27:2444-9. 
59) Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes 
Federation among adults in the U.S. Diabetes Care 2005; 28:2745-9. 
60) Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education 
Program-Adult Treatment Panel III, International Diabetes Federation, and World 
Health Organization definitions of the metabolic syndrome as predictors of incident 
cardiovascular disease and diabetes. Diabetes Care 2007; 30:8-13. 
61) Cameron J, Magliano DJ, Zimmet PZ, Welborn T, Shaw JE. The metabolic syndrome 
in Australia: prevalence using four definitions. Diabetes Res Clin Pract 2007; 77:471-
8. 
62) Kelliny C, William J, Riesen W, Paccaud F, Bovet P. Metabolic syndrome according 
to different definitions in a rapidly developing country of the African region. 
Cardiovasc Diabetol 2008; 7:27. 
63) Deepa M, Farooq S, Datta M, Deepa R, Mohan V. Prevalence of metabolic syndrome 
using WHO, ATP III and IDF definitions in Asian Indians: the Chennai Urban Rural 
Epidemiology Study (Cures -34). Diabetes Metab Res Rev 2007; 23:127-34. 
59 
 
 
64) Hadaegh F, Zabetian A, Tohidi M, Ghasemi A, Sheikholeslami F, Azizi F. Prevalence 
of metabolic syndrome by the Adult Treatment Panel III, International Diabetes 
Federation, and World Health Organization definitions and their association with 
coronary heart disease in an elderly Iranian population. Ann Acad Med Singapore 
2009; 38:142-9. 
65) Xu WH, Ruan XN, Fu XJ, Zhu QL, Zhang H, Bai Y, et al. Prevalence of the metabolic 
syndrome in Pudong New Area of Shanghai using three proposed definitions 
among Chinese adults. BMC Public Health 2010; 10:246. 
66) Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, Tousoulis D, Toutouza M, 
et al. Impact of lifestyle habits on the prevalence of the metabolic syndrome among 
Greek adults form the ATTICA study. Am Heart J 2004; 147:106-12. 
67) Ilanne-Parikka P, Eriksson JG, Lindström J, Hämäläinen H, Keinänen-Kiukaanniemi 
S, Laakso M, et al; Finnish Diabetes Prevention Study Group. Prevalence of the 
metabolic syndrome and its components: findings from a Finnish general population 
sample and the Diabetes Prevention Study cohort. Diabetes Care 2004; 27:2135-40. 
68) Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, et al; InterASIA 
Collaborative Group. Prevalence of the metabolic syndrome and overweight among 
adults in China. Lancet 2005; 365:1398-405. 
69) Zabetian A, Hadaegh F, Azizi F. Prevalence of metabolic syndrome in Iranian adult 
population, concordance between the IDF with the ATPIII and The WHO 
definitions. Diabetes Res Clin Pract 2007; 77:251-7.  
70) Lorenzo C, Serrano-Ríos M, Martínez-Larrad MT, González-Sánchez JL, Seclén S, 
Villena A, et al. Geographic variations of the International Diabetes federation and 
the National Cholesterol Education Program-Adult Treatment Panel III definitions of 
the metabolic syndrome in nondiabetic subjects. Diabetes Care 2006; 29:685-91. 
71) Brown LM, Clegg DJ. Central effects of estradiol in the regulation of food intake, 
body weight and adiposity. J Steroid Biochem Mol Biol 2010; 122:65-73. 
72) Agirbasli M, Agaoglu NB, Orak N, Caglioz H, Ocek T, Poci N, et al. Sex hormones 
and metabolic syndrome in children and adolescents. Metabolism 2009; 58:1256-62. 
73) Ferguson TS, Tulloch-Reid MK, Younger NO, Knight-Madden JM, Samms-Vaughan 
M, Ashley D, et al. Prevalence of the metabolic syndrome and its components in 
relation to socioeconomic status among Jamaican young adults: a cross-sectional 
study.BMC Public Health 2010; 10:307. 
74) Bener A, Mohammad AG, Ismail AN, Zirie M, Abdullatef WK, Al-Hamaq AO. 
Gender and age-related differences in patients with the metabolic syndrome in a 
highly endogamous population. Bosn J Basic Med Sci 2010; 10:210-7. 
75) Sánchez-Chaparro MA, Calvo-Bonacho E, González-Quintela A, Fernández-
Labandera C, Cabrera M, Sáinz JC, et al; Ibermutuamur Cardiovascular Risk 
60 
 
 
Assessment (ICARIA) Study Group. Occupation related differences in the 
prevalence of metabolic syndrome. Diabetes Care 2008; 31:1884-5.  
76) Santos AC, Ebrahim S, Barros H. Gender, socio-economic status and metabolic 
syndrome in middle-aged and old adults. BMC Public Health 2008; 8:62. 
77) Mabry RM, Reeves MM, Eakin EG, Owen N. Gender differences in prevalence of the 
metabolic syndrome in Gulf Cooperation Council Countries: a systematic review. 
Diabet Med 2010; 27:593-97. Review. 
78) Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in 
worldwide populations. Endocrinol Metab Clin North Am 2004; 33:351-75. 
79) Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity 
and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 
50:2362-74. 
80) Ford ES, Li C. Defining the metabolic syndrome in children and adolescents: will the 
real definition please stand up? J Pediatr 2008; 152:160-4. 
81) Mancini MC. Metabolic syndrome in children and adolescents- criteria for diagnosis. 
Diabetol Metab Syndr 2009; 1:20. 
82) Cook S, Auinger P, Li C, Ford ES. Metabolic syndrome rates in United States 
adolescents, from the National Health and Nutrition Examination Survey, 1999-2002. 
J Pediatr 2008; 152:165-70. 
83) Li S, Chen W, Srinivasan SR, Bond MG, Tang R, Urbina EM, et al. Childhood 
cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa 
Heart Study. JAMA 2003; 290:2271-6.  
84) Juonala M, Järvisalo MJ, Mäki-Torkko N, Kähönen M, Viikari JS, Raitakari OT. Risk 
factors identified in childhood and decreased carotid artery elasticity in adulthood: 
the Cardiovascular Risk in Young Finns Study. Circulation 2005; 112:1486-93. 
85) Vanhala MJ, Kumpusalo EA, Pitkäjärvi TK, Takala JK. Metabolic syndrome in a 
middle-aged Finnish population. J Cardiovasc Risk 1997; 4:291-5.  
86) Hu G, Lindström J, Jousilahti P, Peltonen M, Sjöberg L, Kaaja R, et al. The increasing 
prevalence of metabolic syndrome among Finnish men and women over a decade. J 
Clin Endocrinol Metab 2008; 93:832-6. 
87) Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415-
28. 
88) Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart 
Association; National Heart, Lung, and Blood Institute. Definition of metabolic 
Syndrome: Report of the National Heart, Lung and Blood Institute/ American Heart 
Association conference on scientific issues related to definition. Circulation 2004; 
109:433-8. 
89) Reaven G. Why a cluster is truly a cluster: Insulin resistance and cardiovascular 
disease. Clinical Chemistry 2008; 54:785-7. 
61 
 
 
90) Chan JC, Cheung JC, Stehouwer CD, Emeis JJ, Tong PC, Ko GT, et al. The central 
roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the 
Metabolic Syndrome--an analysis by structural equation modelling. Int J Obes Relat 
Metab Disord 2002; 26:994-1008. 
91) Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: 
contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler 
Thromb.2011; 18:629-39.Review. 
92) Antuna-Puente B, Feve B, Fellahi S, Bastard JB. Adipokines: the missing link between 
insulin resistance and obesity. Diabetes Metab 2008; 34:2-11.Review. 
93) Di Chiara T, Argano C, Corrao S, Scaglione R, Licata G. Hypoadiponectinemia: A 
Link between Visceral Obesity and Metabolic Syndrome. J Nutr Metab 2012; 
2012:175245 
94) Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A, et al. Repeatability 
characteristics of simple indices of insulin resistance: implications for research 
applications. J Clin Endocrinol Metab 2001; 86:5457-64. 
95) Blaak EE. Metabolic fluxes in skeletal muscle in relation to obesity and insulin 
resistance. Clin Endocrinol Metab 2005; 19:391-403. Review. 
96) Bouzakri K, Koistinen HA, Ziertah JR. Molecular mechanisms of skeletal muscle 
insulin resistance in type 2 diabetes. Curr Diabetes Rev 2005; 1:167-74. 
97) DeFronzo RA, Gunnarsson R, Björkman O, Olsson M, Wahren J. Effects of insulin on 
peripheral and splanchnic glucose metabolism in non-insulin dependent (type II) 
diabetes mellitus. J Clin Invest 1985; 76:149-55. 
98) Erdmann J, Kallabis B, Oppel U, Sypchenko O, Waagenpfeil S, Schusdziarra V. 
Development of hyperinsulinemia and insulin resistance during the early stage of 
weight gain. Am J Physiol Endocrinol Metab 2008; 294:E568-75. 
99) Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin 
resistance and type 2 diabetes. Nature 2006; 444:840-46. 
100) Hulver MW, Dohm GL. The molecular mechanism linking muscle fat accumulation 
to insulin resistance. Proc Nutr Soc 2004; 63:375-80. 
101) Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest 2000; 106:473-81. 
102) McGarry JD. Banting lecture 2001: Dysregulation of fatty acid metabolism in the 
etiology of type 2 diabetes. Diabetes 2002; 51:7-18. 
103) Ellis BA, Poynten A, Lowy AJ, Furler SM, Chisholm DJ, Kraegen EW, et al. Long-
chain acyl-CoA esters as indicators of lipid metabolism and insulin sensitivity in rat 
and human muscle. Am J Physiol Endocrinol Metab 2000; 279:E554-60. 
104) Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal 
muscle. J Biomed Biotechnol 2010; 2010:476279. 
105) Zeyda M, Stulnig TM. Obesity, inflammation, and insulin resistance--a mini-review. 
Gerontology 2009; 55:379-86. 
62 
 
 
106) Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their 
role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin 
Invest 2002; 32:14-23. 
107) Miyazaki Y, DeFronzo RA. Visceral fat dominant distribution in male type 2 diabetic 
patients is closely related to hepatic insulin resistance, irrespective of body type. 
Cardiovasc Diabetol 2009; 8:44. 
108) Gallagher D, Kelley DE, Yim JE, Spence N, Albu J, Boxt L, et al; MRI Ancillary Study 
Group of the Look AHEAD Research Group. Adipose tissue distribution is different 
in type 2 diabetes. Am J Clin Nutr 2009; 89:807-14.  
109) Kahn SE, Prigeon LR, Schwartz RS, Fujimoto WY, Knopp RH, Brunzell JD, et al. 
Obesity, body fat distribution, insulin sensitivity and islet beta-cell function as 
explanations for metabolic diversity. J Nutr 2001; 131:354S-60S. 
110) Large V, Arner P. Regulation of lipolysis in humans. Pathophysiological modulation 
in obesity, diabetes, and hyperlipidaemia. Diabetes Metab 1998; 24:409-18. 
111) Rytka JM, Wueest S, Schoenle EJ, Konrad D. The portal theory supported by venous 
drainage-selective fat transplantation. Diabetes 2011; 60:56-63. 
112) Yudkin J. Inflammation, obesity and the metabolic syndrome. Horm Metab Res 2007; 
39:707-9. 
113) DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the 
missing links. The Claude Bernard Lecture 2009. Diabetologia 2010; 53:1270-87. 
114) Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, et al. 
Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated 
signaling in human muscle. J Clin Invest 2000; 105:311-20. 
115) Hotamisligil GS. Endoplasmic reticulum stress and the inflammatory basis of 
metabolic disease. Cell 2010; 19:900-17. 
116) Dagogo-Jack S, Askari H, Tykodi G. Glucoregulatory physiology in subjects with 
low-normal, high-normal, or impaired fasting glucose. J Clin Endocrinol Metab 2009; 
94:2031-36.  
117) Stancáková A, Javorský M, Kuulasmaa T, Haffner SM, Kuusisto J, Laakso M. 
Changes in insulin sensitivity and insulin release in relation to glycemia and glucose 
tolerance in 6,414 Finnish men. Diabetes 2009; 58:1212-21.  
118) Abdul-Ghani MA, Tripathy D, DeFronzo RA. Contributions of β-cell dysfunction 
and insulin resistance to the pathogenesis of impaired glucose tolerance and 
impaired fasting glucose. Diabetes Care 2006; 29:1130–9. 
119) Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell dysfunction. 
Endocr Rev 2008; 29:351-66. 
120) Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. 
Med Clin North Am 2011; 95:875-92. Review. 
63 
 
 
121) Rahman S, Ismail AA, Ismail SB, Naing NN, Rahman AR. Early manifestation of 
macrovasculopathy in newly diagnosed never treated type II diabetic patients with 
no traditional CVD risk factors. Diabetes Res Clin Pract 2008; 80:253-8. 
122) Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary 
heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and 
without prior myocardial infarction. N Engl J Med 1998; 339:229–34. 
123) Mercurio V, Carlomagno G, Fazio V, Fazio S. Insulin resistance: Is it time for primary 
prevention? World J Cardiol 2012; 4:1-7. 
124) Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity 
among US adults, 1999-2008. JAMA 2010; 303:235-41.  
125) Nguyen DM, El-Serag HB. The Epidemiology of Obesity. Gastroenterol Clin North 
Am 2010; 39:1-7. 
126) Ramachandran A, Snehalatha C. Rising burden of obesity in Asia. J Obes 2010; 
2010:868573. 
127) World Health Organization. Obesity and Overweight, Fact Sheet No. 311. March 
2011 
128) Peltonen M, Harald K, Männistö S, Saarikoski L, Peltomäki P, Lund L, et al. 
Kansallinen Finriski 2007 -terveystutkimus Tutkimuksen toteutus ja tulokset. 
Kansanterveyslaitoksen julkaisuja B 34/2008. Yliopistopaino. 
Helsinki2008.www.ktl.fi/attachments/suomi/julkaisut/julkaisusarja_b/2008/2008b34.
pdf 
129) Symonds ME, Sebert S, Budge H. The obesity epidemic: from the environment to 
epigenetics - not simply a response to dietary manipulation in a thermoneutral 
environment. Front Genet 2011; 2:24.  
130) Choquet H, Meyre D. Molecular basis of obesity: current status and future prospects. 
Curr Genomics 2011; 12:154-68. 
131) Speakman JR. Thrifty genes for obesity and the metabolic syndrome--time to call off 
the search? Diab Vasc Dis Res 2006; 3:7-11. 
132) Clinical guidelines on the identification, evaluation, and treatment of overweight 
and obesity in adults: executive summary. Expert panel on the Identification, 
Evaluation and Treatment of Overweight in Adults. Am J Clin Nutr 1998; 68:899-917. 
133) Ford ES, Mokdad AH. Epidemiology of obesity in the Western Hemisphere. J Clin 
Endocrinol Metab 2008; 93:S1-8. 
134) Taylor AE, Ebrahim S, Ben-Shlomo Y, Martin RM, Whincup PH, Yarnell JW, et al. 
Comparison of the associations of body mass index and measures of central 
adiposity and fat mass with coronary heart disease, diabetes, and all-cause mortality: 
a study using data from 4 UK cohorts. Am J Clin Nutr 2010; 91:547-56. 
64 
 
 
135) Schneider HJ, Friedrich N, Klotsche J, Pieper L, Nauck M, John U, et al.The 
predictive value of different measures of obesity for incident cardiovascular events 
and mortality. J Clin Endocrinol Metab 2010; 95:1777-85.  
136) Nyamdorj R, Qiao Q, Söderberg S, Pitkäniemi JM, Zimmet PZ, Shaw JE, et al. BMI 
compared with central obesity indicators as a predictor of diabetes incidence in 
Mauritius. Obesity (Silver Spring) 2009; 17:342-8. 
137) Balkau B, Sapinho D, Petrella A, Mhamdi L, Cailleau M, Arondel D, et al; D.E.S.I.R 
Study Group. Prescreening tools for diabetes and obesity-associated dyslipidaemia: 
comparing BMI, waist and waist hip ratio. The D.E.S.I.R. Study. Eur J Clin Nutr 2006; 
60:295-304. 
138) Kvist H, Chowdhury B, Grangård U, Tylén U, Sjöström L. Total and visceral 
adipose-tissue volumes derived from measurements with computed tomography in 
adult men and women: predictive equations. Am J Clin Nutr 1988; 48:1351-61. 
139) Tokunaga K, Matsuzawa Y, Ishikawa K, Tarui S. A novel technique for the 
determination of body fat by computed tomography. Int J Obes 1983; 7:437-45. 
140) Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and 
body composition factors in subgroups of obesity: what do we know? J Clin 
Endocrinol Metab 2004; 89:2569-75. Review. 
141) Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism 
2001; 50:1499-504 .Review. 
142) Arner P. Regional adipocity in man. J Endocrinol 1997; 155:191-192. 
143) Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the 
metabolic syndrome. Endocr Rev 2000; 21:697–738 
144) Carey DG, Nguyen TV, Campbell LV, Chisholm DJ, Kelly P. Genetic influences on 
central abdominal fat: a twin study. Int J Obes Relat Metab Disord 1996; 20:722-6. 
145) Björntorp P. Adipose tissue distribution and function. Int J Obes 1991; 15:67-81. 
146) Kuk JL, Saunders TJ, Davidson LE, Ross R. Age-related changes in total and regional 
fat distribution.  Ageing Res Rev 2009; 8:339-48. 
147) Lee CG, Carr MC, Murdoch SJ, Mitchell E, Woods NF, Wener MH, et al. Adipokines, 
inflammation, and visceral adiposity across the menopausal transition: a prospective 
study. J Clin Endocrinol Metab 2009; 94:1104-10.  
148) Virtue S, Vidal-Puig A. It's not how fat you are, it's what you do with it that counts. 
PLoS Biol 2008; 6:e237. 
149) Huang-Doran I, Sleigh A, Rochford JJ, O'Rahilly S, Savage DB. Lipodystrophy: 
metabolic insights from a rare disorder. Journal of Endocrinology 2010; 207:245-55.  
150) Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and 
ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-
activated receptor agonists provide a rational therapeutic approach. J Clin 
Endocrinol Metab 2004; 89:463-78.  
65 
 
 
151) Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, Hofmann SM, et al. 
Obesity-associated improvements in metabolic profile through expansion of adipose 
tissue. J Clin Invest 2007; 117:2621–37  
152) Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged subcutaneous 
abdominal adipocyte size, but not obesity itself, predicts Type II diabetes 
independent of insulin resistance. Diabetologia 2000; 43:1498–1506 
153) Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-
controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J 
Med 2006; 355:2297-307.  
154) Frayn K. Adipose tissue as a buffer for daily lipid flux.  Diabetologia 2002; 45:1201-
10. 
155) Atzmon G, Yang XM, Muzumdar R, Ma XH, Gabriely I, Barzilai N. Differential gene 
expression between visceral and subcutaneous fat depots. Horm Metab Res 2002; 
34:622-8. 
156) Klimcáková E, Roussel B, Márquez-Quiñones A, Kovácová Z, Kováciková M, 
Combes M, et al. Worsening of obesity and metabolic status yields similar molecular 
adaptations in human subcutaneous and visceral adipose tissue: decreased 
metabolism and increased immune response. J Clin Endocrinol Metab 2011; 96:E73-
82. 
157) Bays HE, González-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, et 
al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte 
hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008; 
6:343-68. Review. 
158) Tan GD, Goossens GH, Humphreys SM, Vidal H, Karpe F. Upper and lower body 
adipose tissue function: a direct comparison of fat mobilization in humans. Obes Res 
2004; 12:114-18. 
159) Smith SR, Lovejoy JC, Greenway F, Ryan D, deJonge L, de la Bretonne J, et al. 
Contributions of total body fat, abdominal subcutaneous adipose tissue 
compartments, and visceral adipose tissue to the metabolic complications of obesity. 
Metabolism 2001; 50:425-35. 
160) Sutherland JP, McKinley B and Eckel RH. The metabolic syndrome and 
inflammation. Metab Syndr Relat Disord 2004; 2:82-104. 
161) Salmenniemi U, Ruotsalainen E, Pihlajamäki J, Vauhkonen I, Kainulainen S, 
Punnonen K, et al. Multiple abnormalities in glucose and energy metabolism and 
coordinated changes in levels of adiponectin, cytokines and adhesion molecules in 
subjects with metabolic syndrome. Circulation 2004; 110:3842-8. 
162) Bahia L, Aguiar LG, Villela N, Bottino D, Godoy-Matos AF, Geloneze B, et al. 
Relationship between adipokines, inflammation, and vascular reactivity in lean 
controls and obese subjects with metabolic syndrome. Clinics 2006; 61:433-40. 
66 
 
 
163) Marsland  AL, McCaffery  JM, Muldoon MF, Manuck SB. Systemic inflammation 
and the metabolic syndrome among middle-aged community volunteers. 
Metabolism 2010; 59:1801-8. 
164) Piñeiro R, Iglesias MJ, Gallego R, Raghay K, Eiras S, Rubio J, et al. Adiponectin is 
synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 2005: 
579;5163-69. 
165) Yokota T, Meka CS, Medina KL, Igarashi H, Comp PC, Takahashi M, et al. Paracrine 
regulation of fat cell formation in bone marrow cultures via adiponectin and 
prostaglandins. J Clin Invest 2002; 109:1303-10. 
166) Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another 
fat cell hormone? Diab Care 2003; 26:2442-50.  
167) Sowers JR. Endocrine functions of adipose tissue: focus on adiponectin. Clin 
Cornerstone  2008; 9:32-8; discussion 39-40. 
168) Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. 
Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin 
resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930-5. 
169) Otsuka F, Sugiyama S, Kojima S, Maruyoshi H, Funahashi T, Sakamoto T, et al. 
Hypoadiponectinemia is associated with impaired glucose tolerance and coronary 
artery disease in non-diabetic men. Circ J 2007; 71:1703-9. 
170) Kawano T, Saito T, Yasu T, Saito T, Nakamura T, Namai K, et al. Close association of 
hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. 
Metabolism 2005; 54:653-6. 
171) Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations 
in women with dyslipidemia. J Clin Endocrinol Metab 2002; 87:2764-9. 
172) Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K, et al. 
Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension 
2004; 43:1318-23. 
173) Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, et al. 
Adiponectin and development of type 2 diabetes in the Pima Indian population. 
Lancet 2002; 360:57-8. 
174) Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma 
adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291:1730–7. 
175) Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to 
malignancies: a review of existing basic research and clinical evidence. Am J Clin 
Nutr 2007; 86:s858-66. Review. 
176) Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient 
energy gauge provides clues to modern understanding of metabolism. Cell Metab 
2005; 1:15-25. 
67 
 
 
177) Okamoto M, Ohara-Imaizumi M, Kubota N, Hashimoto S, Eto K, Kanno T, et al. 
Adiponectin induces insulin secretion in vitro and in vivo at a low glucose 
concentration. Diabetologia 2008; 51:827-35. 
178) Rasmussen MS, Lihn AS, Pedersen SB, Bruun JM, Rasmussen M, Richelsen B. 
Adiponectin receptors in human adipose tissue: effects of obesity, weight loss, and 
fat depots. Obesity 2006; 14:28-35. 
179) Mujumdar PP, Duerksen-Hughes PJ, Firek AF, Hessinger DA. Long-term, 
progressive, aerobic training increases adiponectin in middle-aged, overweight, 
untrained males and females. Scand J Clin Lab Invest 2011; 71:101-7. 
180) Sneddon AA, Tsofliou F, Fyfe CL, Matheson I, Jackson DM, Horgan G, et al. Effect of 
a conjugated linoleic acid and omega-3 fatty acid mixture on body composition and 
adiponectin. Obesity 2008; 16:1019-24.  
181) Takefuji S, Yatsuya H, Tamakoshi K, Otsuka R, Wada K, Matsushita K, et al. 
Smoking status and adiponectin in healthy Japanese men and women. Prev Med 
2007; 45:471-5.  
182) Koh KK, Quon MJ, Lim S, Lee Y, Sakuma I, Lee YH, et al. Effects of fenofibrate 
therapy on circulating adipocytokines in patients with primary 
hypertriglyceridemia. Atherosclerosis 2011; 214:144-7. 
183) Phillips SA, Kung JT. Mechanisms of adiponectin regulation and use as a 
pharmacological target. Curr Opin Pharmacol 2010; 10:676-83. 
184) Dinarello CA. Cytokines as endogenous pyrogens. J Infect Dis 1999; 179:S294-304. 
185) Bujak M, Frangogiannis NG. The role of interleukin-1 in the pathogenesis of heart 
disease. Arch Immunil Ther Exp 2009; 57:165–176 
186) Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 
cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 
2007; 149:217-25. 
187) Olofsson PS, Sheikine Y, Jatta K, Ghaderi M, Samnegård A, Eriksson P, et al. A 
functional interleukin-1 receptor antagonist polymorphism influences 
atherosclerosis development. The interleukin-1β:Interleukin-1 receptos antagonist 
balance in atherosclerosis. Circ J 2009; 73:1531-6. 
188) Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. 
Diabetologia 1996; 39:1005-29. 
189) Loweth AC, Williams GT, James RF, Scarpello JH, Morgan NG. Human islets of 
Langerhans express Fas ligand and undergo apoptosis in response to interleukin-
1beta and Fas ligation. Diabetes 1998; 47:727-32. 
190) Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, et al. 
Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in 
human pancreatic islets. J Clin Invest 2002; 110:851-60. 
68 
 
 
191) Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S, Eizirik DL. Mechanisms of pancreatic 
beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. 
Diabetes 2005; 54; Suppl 2:S97-107. 
192) Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, Berney T, et al. Leptin modulates 
beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human 
islets. Proc Natl Acad Sci U S A 2004; 101:8138-43. 
193) Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Daver JM. IL-1 
receptor antagonist serum levels are increased in human obesity: a possible link to 
the resistance to leptin? J Clin Endocrinol Metab 2002; 87; 1184-8. 
194) Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabák AG, Schloot NC, et al. 
Elevated levels of anti-inflammatory interleukin-1 receptor antagonist precede the 
onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009; 32:421-3. 
195) Stenholm S, Koster A, Alley DE, Visser M, Maggio M, Harris TB, et al. 
Acipocytokines and the metabolic syndrome among older persons with and without 
obesity: the InCHIANTI study. Clin Endocrinol 2010; 73:55-65. 
196) Waehre T, Yndestad A, Smith C, Haug T, Tunheim SH, Gullestad L, et al. Increased 
expression of interleukin-1 in coronary artery disease with downregulatory effects of 
HMG-CoA reductase inhibitors. Circulation 2004; 109:1966-72. 
197) Netea MG, Hancu N, Blok WL, Grigorescu-Sido P, Popa L, Popa V, et al. Interleukin 
1 beta, tumour necrosis factor-alpfa and interleukin 1 receptor antagonist in newly 
diagnosed insulin-dependent diabetes mellitus: comparison to long-standing 
diabetes and healthy individuals. Cytokine 1997; 9:284-7. 
198) Richette P, Francois M, Vicaut E, Fitting C, Bardin T, Corvol M, et al. A high 
interleukin 1 receptor antagonist/IL-1beta ratio occurs naturally in knee 
osteoarthritis. J Rheumatol 2008; 35:1650-4. 
199) Eizirik DL, Tracey DE, Bendtzen K, Sandler S. An interleukin-1 receptor antagonist 
protein protects insulin-producing beta cells against suppressive effects of 
interleukin-1 beta. Diabetologia 1991; 34:445-8. 
200) Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive 
protein and related proteins (pentaxins) and serum amyloid A protein. Adv 
Immunol 1983; 34:141-212. 
201) Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein 
and complement components in atherosclerotic plaques. Am J Pathol 2001; 158:1039-
51. 
202) Sun H, Koike T, Ichikawa T, Hatakeyama K, Shiomi M, Zhang B, et al. C-reactive 
protein in atherosclerotic lesions: its origin and pathophysiological significance. Am 
J Pathol 2005; 167:1139-48. 
69 
 
 
203) Calabro P, Chang DW, Willerson JT, Yeh ET. Release of C-reactive protein in 
response to inflammatory cytokines by human adipocytes: linking obesity to 
vascular inflammation. J Am Coll Cardiol 2005; 46:1112-13. 
204) Pepys MB, Berger A. The renaissance of C-reactive protein. BMJ 2001; 322:4-5. 
205) de Beer FC, Soutar AK, Baltz ML, Trayner IM, Feinstein A, Pepys MB. Low density 
lipoprotein and very low density lipoprotein are selectively bound by aggregated C-
reactive protein. J Exp Med 1982; 156:230-42. 
206) Schindler TH, Cardenas J, Prior JO, Facta AD, Kreissl MC, Zhang XL, et al. 
Relationship between increasing body weight, insulin resistance, inflammation, 
adipocytokine leptin, and coronary circulatory function. J Am Coll Cardiol 2006; 
47:1188-95.  
207) Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 
105:1135-43. 
208) Campbell CY, Nasir K, Wong ND, Blumenthal RS. Role of atherosclerosis assessment 
and other novel markers in the metabolic syndrome. Metab Syndr Relat Disord 2006; 
4:261–9. 
209) Danesh J, Pepys MB. C-reactive protein and coronary disease: is there a causal link? 
Circulation 2009; 120:2036-9. 
210) Koenig W, Sund M, Fröhlich M, Fischer HG, Löwel H, Döring A, et al. C-reactive 
protein, a sensitive marker of inflammation, predicts future risk of coronary heart 
disease in initially healthy middle-aged men: Results from the MONICA 
(Monitoring trends and determinants in cardiovascular disease) Augsburg Cohort 
Study, 1984 to1992. Circulation 1999; 99:237-42. 
211) Ridker PM, Hennekens CH, Buring J, Rifai N. C-reactive protein and other markers 
of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 
2000; 342:836-43. 
212) Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-
reactive protein and other circulating markers of inflammation in the prediction of 
coronary heart disease. N Engl J Med 2004; 350:1387-97. 
213) Fröhlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. 
Association between C-reactive protein and features of the metabolic syndrome: a 
population-based study. Diabetes Care 2000; 23:1835-9. 
214) Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM. Chronic 
subclinical inflammation as part of the insulin resistance syndrome: the insulin 
resistance atherosclerosis study (IRAS).Circulation 2000; 102:42-7. 
215) Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to 
metabolic syndrome and to assessment of global cardiovascular risk? Circulation 
2004; 109:2818-25. 
70 
 
 
216) Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic 
syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 
initially healthy American women. Circulation 2003; 107:391-7. 
217) Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, et 
al; Centers for Disease Control and Prevention; American Heart Association. 
Markers of inflammation and cardiovascular disease. Application to clinical and 
public health practice: A statement for healthcare professionals from the Centers for 
Disease Control and Prevention and the American Heart Association. Circulation 
2003; 107:499-511. 
218) Oda E, Oohara K, Abe A, Veeraveedu PT, Watanabe K, Kato K, et al. The optimal 
cut-off point of C-reactive protein as an optional component of metabolic syndrome 
in Japan. Circ J 2006; 70:384-8. 
219) Yudkin JS, Juhan-Vague I, Hawe E, Humphries SE, diMinno G, Margaglione M, et al: 
HIFMECH Study Group. Low-grade inflammation may play a role in the etiology of 
the metabolic syndrome in patients with coronary heart disease: the HIFMECH 
study. Metabolism 2004; 53:852-7. 
220) Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of 
conventional risk factors in patients with coronary heart disease. JAMA 2003; 
290:898-904. 
221) Tilg H, Moschen AR. Inflammatory mechanisms in the regulation of insulin 
resistance. Mol Med 2008; 14:222-31. 
222) Xydakis AM, Case CC, Jones PH, Hoogeveen RC, Liu MY, Smith EO, et al. 
Adiponectin, inflammation, and the expression of the metabolic syndrome in obese 
individuals: the impact of rapid weight loss through caloric restriction. J Clin 
Endocrinol Metab 2004; 89:2697-703. 
223) Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. 
Serum immunoreactive-leptin concentrations in normal-weight and obese humans. 
N Engl J Med 1996; 334:292-5. 
224)  Ahima RS. Revisiting leptin's role in obesity and weight loss. J Clin Invest 2008; 
118:2380-3. 
225) Boozer CN, Leibel RL, Love RJ, Cha MC, Aronne LJ. Synergy of sibutramine and 
low-dose leptin in treatment of diet-induced obesity in rats. Metabolism 2001; 50:889-
93. 
226) Franks PW, Brage S, Luan J, Ekelund U, Rahman M, Farooqi IS, et al. Leptin predicts 
a worsening of the features of the metabolic syndrome independently of obesity. 
Obes res 2005; 13:1476-84. 
227) Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances 
in the relationship between obesity, inflammation, and insulin resistance. Eur 
Cytokine Netw 2006; 17:4-12. 
71 
 
 
228) Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadei L, et al. 
Insulin resistance in essential hypertension. N Engl J Med 1987; 317:350-7. 
229) Pollare T, Lithell H, Berne C. Insulin resistance is a characteristic feature of primary 
hypertension independent of obesity. Metabolism 1990; 39:167-74. 
230) DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on 
renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest  
1975; 55:845-55. 
231) Kuroda S, Uzu T, Fujii T, Nishimura M, Nakamura S, Inenaga T, et al. Role of insulin 
resistance in the genesis of sodium sensitivity in essential hypertension.  J Hum 
Hypertens 1999; 13:257-62. 
232) Han KA, Patel Y, Lteif AA, Chisholm R, Mather KJ. Contributions of dysglycaemia, 
obesity, and insulin resistance to impaired endothelium-dependent vasodilation in 
humans. Diabetes Metab Res Rev 2011; 27:354-61. 
233) Bautista LE. Inflammation, endothelial dysfunction, and the risk of high blood 
pressure: epidemiologic and biological evidence. J Hum Hypertens 2003; 17:223-30. 
234) Schillaci G, Pirro M. Hypoadiponectinemia: a novel link between obesity and 
hypertension? Hypertension 2007; 49:1217-9.  
235) Hingorani AD, Cross J, Kharbanda RK, Mullen MJ, Bhagat K, Taylor M, et al. Acute 
systemic inflammation impairs endothelium-dependent dilatation in humans. 
Circulation 2000; 102:994-9. 
236) Dorrance AM. Interleukin 1-beta (IL-1beta) enhances contractile responses in 
endothelium-denuded aorta from hypertensive, but not normotensive, rats. 
VasculPharmacol 2007; 47:160-5. 
237) Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, et al. Prognostic 
value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 
43:1817-22. 
238) Mulé G, Nardi E, Cottone S, Cusimano P, Palermo A, Incalcaterra F, et al. Impact of 
the metabolic syndrome on total arterial compliance in essential hypertension 
patients. J Cardiometab Syndr 2007; 2:84-90. 
239) Schillaci G, Pirro M, Vaudo G, Mannarino MR, Savarese G, Pucci G, et al. Metabolic 
syndrome is associated with aortic stiffness in untreated essential hypertension. 
Hypertension 2005; 45:1078-82.  
240) Sciarretta S, Ferrucci A, Ciavarella GM, De Paolis P, Venturelli V, Tocci G, et al. 
Markers of inflammation and fibrosis are related to cardiovascular damage in 
hypertensive patients with metabolic syndrome.  Am J Hypertens 2007; 20:784-91. 
241) Waheed P, Naveed AK, Farooq F. Levels of inflammatory markers and their 
correlation with dyslipidemia in diabetics.  J Coll Physicians Surg Pak 2009; 19:207-
10. 
72 
 
 
242) Rivera JJ, Nasir K, Campbell C, Carvalho JA, Blumenthal RS, Santos RD. Relation of 
plasma lipoprotein levels with low-grade inflammation in white men without 
clinical evidence of myocardial ischemia. Am J Cardiol 2007; 100:450-4.  
243) Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, Grunfeld C, et al. 
Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 1995; 
136:2143-9. 
244) Gómez Rosso L, Meroño T, Benítez MB, López G, Giunta G, D'Ambrosio ML, et al. 
Low adiponectin levels in primary hypertriglyceridemic male patients.  Nutr Metab 
Cardiovasc Dis 2009; 19:135-9.  
245) Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of 
fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic 
fatty liver disease. J Clin Invest 2005; 115:1343-51. 
246) Bloomgarden ZT. Second World Congress on the Insulin Resistance Syndrome: 
insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care 2005; 
28:1518–23 
247) Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, et al. Metabolic significance of 
nonalcoholic fatty liver disease in nonobese, nondiabetic adults.  Arch Intern Med 
2004; 164:2169-75. 
248) Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The 
metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern 
Med 2005; 143:722–8. 
249) Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, et al. Fatty 
liver is associated with dyslipidemia and dysglycemia independent of visceral fat: 
the Framingham Heart Study. Hepatology  2010; 51:1979-87. 
250) Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization 
in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002; 
23:201-29. 
251) Bugianesi E, Pagotto U, Manini R, Vanni E, Gastaldelli A, de Iasio R, et al. Plasma 
adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and 
hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab 2005; 
90:3498–3504. 
252) Faulds MH, Dahlman-Wright K. Metabolic diseases and cancer risk. Curr Opin 
Oncol 2012; 24:58-61. 
253) Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of 
impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. 
Diabetes Care 1999; 22:141–6. 
254) Cho LW, Atkin SL. Cardiovascular risk in women with polycystic ovary syndrome. 
Minerva Endocrinol 2007; 32:263–73. 
73 
 
 
255) Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi 
MN:PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic 
syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006; 
91:48–53. 
256) González F. Inflammation in polycystic ovary syndrome: underpinning of insulin 
resistance and ovarian dysfunction. Steroids 2012; 77:300-5. 
257) Farrell JB, Deshmukh A, Baghaie AA. Low testosterone and the association with type 
2 diabetes. Diabetes Educ 2008; 34:799-806. 
258) Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex 
hormone-binding globulin, total testosterone, and symptomatic androgen deficiency 
are associated with development of the metabolic syndrome in nonobese men. J Clin 
Endocrinol Metab 2006; 91: 843 –50. 
259) Corona G, Mannucci E, Petrone L, Balercia G, Paggi F, Fisher AD, et al. NCEP-
ATPIII-defined metabolic syndrome, type 2 diabetes mellitus, and prevalence of 
hypogonadism in male patients with sexual dysfunction. J Sex Med 2007; 4:1038-45. 
260) Saad F, Gooren LJ, Haider A, Yassin A. A dose response study of testosterone on 
sexual dysfunction and on features of the metabolic syndrome using testosterone gel 
and parenteral testosterone undecanoate. J Androl 2008; 29:102–5. 
261) Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of 
testosterone supplementation on markers of the metabolic syndrome and 
inflammation in hypogonadal men with the metabolic syndrome: the double-blinded 
placebo-controlled Moscow study. Clin Endocrinol 2010; 73:602-12. 
262) Peled N, Kassirer M, Shitrit D, Kogan Y, Shlomi D, Berliner AS, et al.The association 
of OSA with insulin resistance, inflammation and metabolic syndrome. Respir Med 
2007; 101:1696-701. 
263) Parish JM, Adam T, Facchiano L. Relationship of metabolic syndrome and 
obstructive sleep apnea. J Clin Sleep Med 2007; 3:467-72. 
264) Perseghin G, Calori G, Lattuada G, Ragogna F, Dugnani E, Garancini MP, et al. 
Insulin resistance/hyperinsulinemia and cancer mortality: the Cremona study at the 
15th year of follow-up. Acta Diabetol 2012 DOI: 10.1007/s00592-011-
0361.PMID:22215126. 
265) Healy LA, Ryan AM, Carroll P, Ennis D, Crowley V, Boyle T, et al. Metabolic 
syndrome, central obesity and insulin resistance are associated with adverse 
pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol) 
2010; 22:281-8.  
266) Doyle SL, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic 
syndrome, insulin resistance and cancer. Proc Nutr Soc 2012; 71:181-9. 
267) Nakashita Y, Nakamura M, Kitamura A, Kiyama M, Ishikawa Y, Mikami H. 
Relationships of cigarette smoking and alcohol consumption to metabolic syndrome 
in Japanese men. J Epidemiol 2010; 20:391-7. 
74 
 
 
268) Weitzman M, Cook S, Auinger P, Florin TA, Daniels S, Nguyen M, et al. Tobacco 
smoke exposure is associated with the metabolic syndrome in adolescents. 
Circulation 2005; 112:862–9. 
269) Eliasson B. Cigarette smoking and diabetes. Prog Cardiovasc Dis 2003; 45:405-13.  
270) Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of 
type 2 diabetes: a systematic review and meta-analysis. JAMA 2007; 298:2654–64. 
271) Foy CG, Bell RA, Farmer DF, Goff DC Jr, Wagenknecht LE. Smoking and incidence 
of diabetes among U.S. adults: findings from the Insulin Resistance Atherosclerosis 
Study. Diabetes Care 2005; 28:2501-7 
272) Shimokata H, Muller DC, Andres R. Studies in the distribution of body fat. III. 
Effects of cigarette smoking. JAMA 1989; 261:1169–73. 
273) Clair C, Chiolero A, Faeh D, Cornuz J, Marques-Vidal P, Paccaud F, et al. Dose-
dependent positive association between cigarette smoking, abdominal obesity and 
body fat: cross-sectional data from a population-based survey. BMC Public Health 
2011; 11:23. 
274) van der Vaart H, Postma DS, Timens W, ten Hacken NH. Acute effects of cigarette 
smoke on inflammation and oxidative stress: a review. Thorax 2004; 59:713-21. 
275) Helmersson, J, Larsson, A, Vessby, B, Basu S. Active smoking and a history of 
smoking are associated with enhanced prostaglandin F (2α), interleukin-6 and F2-
isoprostane formation in elderly men. Atherosclerosis 2005; 181:201-7. 
276) Thamer C, Stefan N, Stumvoll M, Häring H, Fritsche A. Reduced adiponectin serum 
levels in smokers. Atherosclerosis 2005; 179:421-2. 
277) Iwashima Y, Katsuya T, Ishikawa K, Kida I, Ohishi M, Horio T, et al. Association of 
hypoadiponectinemia with smoking habit in men. Hypertension 2005; 45:1094-100. 
278) Efstathiou SP, Skeva II, Dimas C, Panagiotou A, Parisi K, Tzanoumis L, et al. 
Smoking cessation increases serum adiponectin levels in an apparently healthy 
Greek population. Atherosclerosis 2009; 205:632-6. 
279) Otsuka F, Kojima S, Maruyoshi H, Kojima S, Matsuzawa Y, Funahashi T, et al. 
Smoking cessation is associated with increased plasma adiponectin levels in men. J 
Cardiol 2009; 53:219-25. 
280) Reichert V, Xue X, Bartscherer D, Jacobsen D, Fardellone C, Folan P, et al. A pilot 
study to examine the effects of smoking cessation on serum markers of inflammation 
in women at risk for cardiovascular disease. Chest 2009; 136:212-9.  
281) Bakhru A, Erlinger TP. Smoking cessation and cardiovascular disease risk factors: 
results from the Third National Health and Nutrition Examination Survey. PLos 
Med 2005; 2:e160. 
282) Albanes D, Jones DY, Micozzi MS, Mattson ME. Associations between smoking and 
body weight in the US population: analysis of NHANES II. Am J Public Health 1987; 
77:439–444. 
75 
 
 
283) Tankó LB, Christiansen C. An update on the antiestrogenic effect of smoking: a 
literature review with implications for researchers and practitioners. Menopause 
2004; 11:104-9. 
284) Haarbo J, Marslew U, Gotfredsen A, Christiansen C. Postmenopausal hormone 
replacement therapy prevents central distribution of body fat after menopause. 
Metabolism 1991; 40:1323–6. 
285) Zamboni M, Zoico E, Scartezzini T, Mazzali G, Tosoni P, Zivelonghi A, et al. Body 
composition changes in stable-weight elderly subjects: the effect of sex. Aging Clin 
Exp Res 2003; 15:321-7.  
286) Vermeulen A, Goemaere S, Kaufman JM. Testosterone, body composition and aging. 
J Endocrinol Invest 1999; 22(5 Suppl):110–16. 
287) Direk N, Newson RS, Hofman A, Kirschbaum C, Tiemeier H. Short and long-term 
effects of smoking on cortisol in older adults. Int J Psychophysiol 2011; 80:157–60.  
288) Vreeburg SA, Kruijtzer BP, van Pelt J, van Dyck R, DeRijk RH, Hoogendijk WJ, et al. 
Associations between sociodemographic, sampling and health factors and various 
salivary cortisol indicators in a large sample without psychopathology. 
Psychoneuroendocrinology 2009; 34:1109–20. 
289) Soldin OP, Makambi KH, Soldin SJ, O'Mara DM. Steroid hormone levels associated 
with passive and active smoking. Steroids 2011; 76:653-9. 
290) Pasquali R, Vicennati V. Activity of the hypothalamic-pituitary-adrenal axis in 
different obesity phenotypes. Int J Obes Relat Metab Disord 2000; 24Suppl2:S47–9. 
291) Serdula MK, Byers T, Mokdad AH, Simoes E, Mendlein JM, Coates RJ. The 
association between fruit and vegetable intake and chronic disease risk factors. 
Epidemiology 1996; 7:161-5. 
292) Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease 
associated with diabetes in men and women: meta-analysis of 37 prospective cohort 
studies. BMJ 2006; 332:73-8.  
293) Henry RMA, Kamp O, Kostense PJ, Spijkerman AMW, Dekker JM, van Eijck R, et al; 
Hoorn study. Left ventricular mass increases with deteriorating glucose tolerance, 
especially in women: independence of increased arterial stiffness or decreased flow-
mediated dilation: the Hoorn Study. Diabetes Care 2004; 27: 522–9. 
294) Han TS, Sattar N, Williams K, Gonzalez-Villalpando C, Lean ME, Haffner SM. 
Prospective study of C-reactive protein in relation to the development of diabetes 
and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care 2002; 
25:2016–21. 
295) Sander K, Horn CS, Briesenick C, Sander D; INVADE Study Group. High-sensitivity 
C-reactive protein is independently associated with early carotid artery progression 
in women but not in men: the INVADE Study. Stroke 2007; 38:2881-6. 
76 
 
 
296) Ybarra J, Lehmann TN, Golay A, Juge-Aubry CE, Roux-Lombard P, Dayer JM, et al. 
Gender-based dimorphic pattern for interleukin-1 receptor antagonist in type 2 
diabetes mellitus.  Diabetes Metab 2008; 34:75-81.  
297) Böttner A, Kratzsch J, Müller G, Kapellen TM, Blüher S, Keller E, et al. Gender 
differences of adiponectin levels develop during the progression of puberty and are 
related to serum androgen levels. J Clin Endocrinol Metab 2004; 89:4053-61. 
298) Mankad R, Best PJ. Cardiovascular disease in older women: a challenge in diagnosis 
and treatment. Womens Health 2008; 4:449-64. 
299) Pérez-López FR, Larrad-Mur L, Kallen A, Chedraui P, Taylor HS. Gender differences 
in cardiovascular disease: hormonal and biochemical influences. Reprod Sci 2010; 
17:511-31. 
300) Hyde Z, Norman PE, Flicker L, Hankey GJ, Almeida OP, McCaul KA, et al. Low free 
testosterone predicts mortality from cardiovascular disease but not other causes: the 
Health in Men Study. J Clin Endocrinl Metab 2012; 97:179-89.  
301) Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, et al. Hypogonadism 
as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J 
Endocrinol 2011; 165:687-701.  
302) Lindquist R, Boucher JL, Grey EZ, Cairns B, Bobra S, Windenburg D, et al. 
Eliminating untimely deaths of women from heart disease: highlights from the 
Minnesota Women's Heart Summit. Am J Heart 2012; 163:39-48.e1. 
303) Evangelista O, McLaughlin MA. Review of cardiovascular risk factors in women. 
Gend Med 2009; 6 Suppl 1:17-36. 
304) Stern MP, Williams K, González-Villalpando C, Hunt KJ, Haffner SM. Does the 
metabolic syndrome improve identification of individuals at risk of type 2 diabetes 
and/or cardiovascular disease? Diabetes Care 2004; 27:2676-81. 
305) Kahn R: The metabolic syndrome (emperor) wears no clothes (Commentary). 
Diabetes Care 2006; 29:1693–6. 
306) Grundy SM. Does the metabolic syndrome exist? Diabetes Care 2006; 29:1689-92; 
discussion 1693-6. 
307) Davidson MB. Does the metabolic syndrome exist: response to Grundy. Diabetes 
Care 2006; 29:2565. 
308) Bakke P, Gulsvik A, Lilleng P, Overå O, Hanoa R, Eide GE. Postal survey on airborne 
occupational exposure and respiratory disorders in Norway: causes and 
consequences of non-response. J Epidemiol Community Health 1990; 44:316-20.  
309) Melbye H, Hvidsten D, Holm A, Nordbø SA. Brox J. The course of C-reactive protein 
response in untreated upper respiratory tract infection. Br J Gen Pract 2004; 54:653-8. 
310)  Gulich MS, Matschiner A, Glück R, Zeitler HP. Improving diagnostic accuracy of 
bacterial pharyngitis by near patient measurement of C-reactive protein (CRP). Br J 
Gen Pract 1999; 49:119-21. 
77 
 
 
311) Schraw T, Wang ZV, Halberg N, Hawkins M , Scherer PE. Plasma Adiponectin 
Complexes Have Distinct Biochemical Characteristics. Endocrinology 2008; 149: 
2270–2282.  
312) Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of Adiponectin 
with Coronary Heart Disease and Mortality: The Rancho Bernardo Study. Am J 
Epidemiol 2007; 15:164-74. 
313) Tworoger SS, Hankinson SE. Collection, processing, and storage of biological 
samples in epidemiologic studies: sex hormones, carotenoids, inflammatory 
markers, and proteomics as examples. Cancer Epidemiol Biomarkers Prev 2006; 
15:1578-81. 
314) Stommel M, Schoenborn CA. Accuracy and usefulness of BMI measures based on 
self-reported weight and height: findings from NHANES & NHIS 2001-2006. BMC 
Public Health 2009; 9:421. 
315) Casey VA, Dwyer JT, Berkey CS, Coleman KA, Gardner J, Valadian I. Long-term 
memory of body weight and past weight satisfaction: a longitudinal follow-up 
study. Am J Clin Nutr 1991; 53:1493-8. 
316) www.stakes.fi/FI/tilastot/aiheittain/Paihteet/tupakka.htm  
317) Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP, et al. 
Complex distribution, not absolute amount of adiponectin, correlates with 
thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004; 
279:12152-62. 
318) Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma 
concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic 
patients. Arterioscler Thromb Vasc Biol 2000; 20:1595 –9. 
319) Vozarova B, Stefan N, Lindsay RS, Krakoff J, Knowler WC, Funahashi T, et al. Low 
plasma adiponectin concentrations do not predict weight gain in humans. Diabetes 
2002; 51:2964-7. 
320) Langenberg C, Bergstrom J, Laughlin GA, Barrett-Connor E. Ghrelin, adiponectin, 
and leptin do not predict long-term changes in weight and body mass index in older 
adults: longitudinal analysis of the Rancho Bernardo cohort. Am J Epidemiol 2005; 
162:1189-97.  
321) Ludescher B, Najib A, Baar S, Machann J, Thamer C, Schick F, et al. Gender specific 
correlations of adrenal gland size and body fat distribution: a whole body MRI 
study. Horm Metab Res 2007; 39:515-8. 
322) Sowers M, Zheng H, Tomey K, Karvonen-Gutierrez C, Jannausch M, Li X, et al. 
Changes in body composition in women over six years at midlife: ovarian and 
chronological aging. J Clin Endocrinol Metab 2007; 92:895-901. 
323) Lobo RA. Metabolic syndrome after menopause and the role of hormones. Maturitas 
2008; 60:10-8.  
78 
 
 
324) Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. 
Relationship of adiponectin to body fat distribution, insulin and plasma lipoproteins: 
evidence for independent roles of age and sex. Diabetologia 2003; 46:459-69.  
325) Westerbacka J, Corner A, Tiikkainen M, Tamminen M, Vehkavaara S, Häkkinen AM, 
et al. Women and men have similar amounts of liver and intra-abdominal fat, 
despite more subcutaneous fat in women: implications for sex differences in markers 
of cardiovascular risk. Diabetologia 2004; 47:1360-9. 
326) Pitombo C, Araújo EP, De Souza CT, Pareja JC, Geloneze B, Velloso LA. 
Amelioration of diet-induced diabetes mellitus by removal of visceral fat. J 
Endocrinol 2006; 191:699–706. 
327) Gabriely I, Ma XH, Yang XM, Atzmon G, Rajala MW, Berg AH, et al. Removal of 
visceral fat prevents insulin resistance and glucoseintolerance of aging: an 
adipokine-mediated process? Diabetes 2002; 51:2951–8. 
328) Ueland T, Kristo C, Godang K, Aukrust P, Bollerslev J. Interleukin-1 receptor 
antagonist is associated with fat distribution in endogenous Cushing’s syndrome: a 
longitudinal study. J Clin Endocrinol Metab 2003; 88:1492-6. 
329) Mandrup-Poulsen T. Beta-Cell apoptosis: stimuli and signaling. Diabetes 2001; 50 
Suppl 1:S58-63. Review. 
330) Bridevaux PO, Gerbase MW, Schindler C, Dietrich DF, Curjuric I, Dratva J, et al. Sex-
specific effect of body weight gain on systemic inflammation in subjects with COPD: 
results from the SAPALDIA cohort study 2. Eur Respir J 2009; 34:332-9. 
331) Fransson EI, Batty GD, Tabák AG, Brunner EJ, Kumari M, Shipley MJ, et al. 
Association between change in body composition and change in inflammatory 
markers: an 11-year follow-up in the Whitehall II Study. J Clin Endocrinol Metab 
2010; 95:5370-4. 
332) Manios Y, Panagiotakos DB, Pitsavos C, Polychronopoulos E, Stefanadis C. 
Implication of socio-economic status on the prevalence of overweight and obesity in 
Greek adults: the ATTICA study. Health Policy 2005; 74:224-32. 
333) Gnavi R, Spagnoli TD, Galotto C, Pugliese E, Carta A, Cesari L. Socioeconomic 
status, overweight and obesity in prepubertal children: a study in an area  of 
Northern Italy. Eur J Epidemiol 2000; 16:797-803. 
334) Sonmez A, Dogru T, Yilmaz MI, Tasci I, Ocal R, Ozgurtas T, et al. Adiponectin and 
insulin resistance in young and healthy smokers. Endocr J 2006; 53:729-34. 
335) Georges E, Mueller WH, Wear ML. Body fat distribution in men and women of the 
Hispanic health and nutrition examination survey of the United States: associations 
with behavioural variables. Ann Hum Biol 1993; 20:275-91. 
336) Daniel M, Martin AD, Faiman C. Sex hormones and adipose tissue distribution in 
premenopausal cigarette smokers. Int J Obes Relat Metab Disord 1992; 16:245-54. 
79 
 
 
337) García-Lorda P, Bulló M, Balanzà R, Salas-Salvadó J.C-reactive protein, adiposity 
and cardiovascular risk factors in a Mediterranian population. Int J Obes 2006; 
30:468-74. 
338) Fröhlich M, Sund M, Löwel H, Imhof A, Hoffmeister A, Koenig W. Independent 
association of various smoking characteristics with markers of systemic 
inflammation in men. Results from a representative sample of the general 
population (MONICA Augsburg Survey 1994/1995). Eur Heart J 2003; 24:1365-72. 
339) Olafsdóttir IS, Gíslason T, Thjódleifsson B, Olafsson I, Gíslason D, Jõgi R, et al.  
Gender differences in the association between C-reactive protein, lung function 
impairment, and COPD. Int J Chron Obstruct Pulmon Dis 2007; 2:635-42. 
340) Bermudez EA, Rifai N, Buring J, Manson JE, Ridker PM. Interrelationships among 
circulating interleukin-6,C-reactive protein and traditional cardiovascular risk 
factors in women. Arterioscler Thromb Vasc Biol 2002; 22:1668-73. 
341) Fain JN. Release of interleukins and other inflammatory cytokines by human adipose 
tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm 2006; 
74:443-77. 
342) Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of 
obese subjects release interleukin-6: depot difference and regulation by 
glucocorticoid. J Clin Endocrinol Metab 1998; 83:847-50. 
343) Blouin K, Boivin A, Tchernof A. Androgens and body fat distribution. J Steroid 
Biochem Mol Biol 2008; 108:272-80. 
344) You T, Ryan AS, Nicklas BJ. The metabolic syndrome in obese postmenopausal 
women: relationship to body composition, visceral fat, and inflammation. J Clin 
Endocrinol Metab 2004; 89:5517-22 
345) Galve-de Rochemonteix B, Wiktorowicz K, Kushner I, Dayer JM. C-reactive protein 
increases production of IL-1 alpha, IL-1 beta, and TNF-alpha, and expression of 
mRNA by human alveolar macrophages. J Leukoc Biol 1993; 53:439-45. 
346) Nakanishi N, Shiraishi T, Wada M. C-reactive protein concentration is more strongly 
related to metabolic syndrome in women than in men: the Minoh Study. Circ J 2005; 
69:386-91. 
347) Snijder MB, Dekker JM, Visser M, Stehouwer CD, Yudkin JS, Bouter LM, et al. 
Prospective relation of C-reactive protein in type 2 diabetes. Diab Care 2003; 26:1656-
8. 
348) Doi Y, Kiyohara Y, Kubo M, Ninomiya T, Wakugava Y, Yonemoto K, et al. Elevated 
C-reactive protein is a predictor of the development of diabetes in a general Japanese 
population: the Hisayama Study. Diab Care 2005; 28:2497-500. 
349) Kashyap SR, Defronzo RA. The insulin resistance syndrome: physiological 
considerations. Diab vasc dis res 2007; 4:13-9. Review. 
80 
 
 
350) Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res 
Rev 2002; 18:S5-S9. Review.  
351) Carnethon MR, Loria CM, Hill JO, Sidney S, Savage PJ, Liu K.Y Risk factors for the 
metabolic syndrome: the Coronary Artery Risk Development in Young Adults 
(CARDIA) study, 1985-2001. Diabetes Care 2004; 27:2707-15 
352) Lundgren JD, Malcolm R, Binks M, O’Neil PM. Remission of metabolic syndrome 
following a 15-week low-calorie lifestyle change program for weight loss. Int J Obes 
2009; 33:144-50. 
353) Lloyd-Jones DM, Liu K, Colangelo LL, Yan LJ, Klein L, Loria CM, et al. Consistently 
stable or decreased body mass index in young adulthood and longitudinal changes 
in metabolic syndrome components: the Coronary Artery Risk Development in 
Young Adults Study. Circulation 2007; 115:1004-11. 
354) Steffen R, Potoczna N, Bieri N, Horber FF. Successful multi intervention treatment of 
severe obesity: a 7-year prospective study with 96% follow-up. Obesity Surgery 2009; 
19:3-12. 
355) Renaldi O, Pramono B, Sinorita H, Purnomo LB, Asdie RH, Asdie AH. 
Hypoadiponectinemia: a risk factor for metabolic syndrome. Acta Med Indones 2009; 
4:20-4. 
356) Luotola K, Pietilä A, Zeller T, Moilanen L, Kähönen M, Nieminen MS, et al; Health 
2000 and FINRISK97 Studies. Associations between interleukin-1 (IL-1) gene 
variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. 
J Intern Med 2011; 269:322-32. 
357) Dinarello CA. Interleukin-1 beta, interleukin-18, and the interleukin-1 beta 
converting enzyme. Ann N Y Acad Sci 1998; 856:1-11. 
358) Li JT, Hou FF, Guo ZJ, Shan YX, Zhang X, Liu ZQ. Advanced glycation end products 
upregulate C-reactive protein synthesis by human hepatocytes through stimulation 
of monocyte IL-6 and IL-1 beta production. Scand J Immunol 2007; 66:555-62. 
359) Genest J. C-reactive protein: risk factor, biomarker and/or therapeutic target? Can J 
Cardiol 2010; 26 Suppl A: 41A-44A. Review. 
360) Larsen CM, Faulenbach M, Vaag A, Ehses JA, Donath MY, Mandrup-Poulsen T. 
Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. 
Diabetes Care 2009; 32:1663-8.  
 
Publications of the University of Eastern Finland
Dissertations in Health Sciences
isbn 978-952-61-0951-0
Publications of the University of Eastern Finland
Dissertations in Health Sciences
d
issertatio
n
s | 137 | T
iin
a M
a
a
r
it A
h
o
n
en
 | A
dip
on
ectin an
d L
ow
-G
rade Infl
am
m
ation in R
elation to P
recedin
g F
actors an
d th
e C
ourse of th
e...
Tiina Maarit Ahonen
Adiponectin and Low-Grade 
Inflammation in Relation to 
Preceding Factors and the 
Course of the Metabolic 
Syndrome
A Gender-Specific View
Tiina Maarit Ahonen
Adiponectin and Low-Grade 
Inflammation in Relation to 
Preceding Factors and the 
Course of the Metabolic Syndrome
A Gender-Specific View
Inflammation, which is associated 
with the metabolic syndrome, was 
examined in relation to preceding 
factors of this syndrome. The 
results show that, from the aspect 
of inflammation, an increase in 
relative weight is more harmful 
to women than to men. Females 
who smoke may be more prone to 
development of inflammatory state 
due to lower adiponectin levels, 
compared to males. Increased low-
grade inflammation at baseline may 
refer to an unfavorable course of the 
metabolic syndrome in both genders.
